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1.5 Summary
Opportunistic pathogens like Pseudomonas aeruginosa become increasingly re-
sistant to antibiotics, and therefore represent a major threat to patients. Thus,
we urgently need new approaches to fight multi-resistant pathogens. It has
been suggested that, instead of targeting vital cell mechanisms, virulence fac-
tors could be inhibited with so-called anti-virulence treatments. These treat-
ments are believed to impose lower selection pressure on the pathogen and
would thereby reduce the risk of resistance development. In this thesis, we aim
to extend the anti-virulence approach by targeting a secreted virulence factor
that is cooperatively shared between bacteria. For many pathogens, coopera-
tion is essential to infect hosts, and is often mediated by secreted, publically
shared virulence factors. Cooperating individuals can be exploited by indi-
viduals, which do not contribute to cooperation, but reap the benefits from it,
so-called cheaters. By targeting a cooperatively shared virulence factor, the co-
operating community becomes phenotypic cheaters and every individual, that
resumes cooperation (e.g. by developing resistance), will be exploited immedi-
ately and thus resistance is not favoured by natural selection. Such a treatment
can become evolution proof.
We tested this idea by inhibiting the cooperatively shared virulence factor py-
overdine. Pyoverdine is the main siderophore of P. aeruginosa, which is de-
ployed in severely iron-limited environments to assure sufficient supply of this
essential nutrient. Pyoverdine facilitates pathogenic growth at the infection site.
In chapter (3) we experimentally tested a promising candidate, the transition
metal gallium, as an evolution proof anti-virulence treatment, that targets py-
overdine. Gallium effectively curbed the virulence of P. aeruginosa in an insect
model. Moreover, while antibiotics lost their efficacy rapidly in an evolution
experiment, P. aeruginosa did not show signs of resistance to gallium.
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Next, we tested if and how such interference with virulence factor availability
(pyoverdine) feeds back on the pathogen, its regulatory network and the host
(chapter 4). We found complex relationships between these variables. While the
link between virulence factor availability and virulence was positive, pyover-
dine availability did not correlate monotonously with pathogen growth within
the host. The amount of available virulence factor influenced the expression of
virulence factors, that are regulatorily linked. Additionally, it triggered differ-
ential host immune responses. These findings highlight the necessity to closely
evaluate the effects of any anti-virulence drug on the pathogen and the host, in
order to design effective drugs with a predictive treatment outcome.
The concept of evolution proof anti-virulence treatments builds (among oth-
ers) on the assumption that the targeted virulence factor is collectively shared
between individuals. Although pyoverdine cooperation has been extensively
studied in the last decade, almost all studies feature experiments in batch cul-
tures. However, little is known about whether the insights from batch culture
experiments can be transferred to infections. In the host, cell numbers might be
lower and bacteria might interact on the micrometre-scale in a spatially struc-
tured environment where diffusion of a shared virulence factor, and thus share-
ability, could be limited. Therefore, we investigated pyoverdine sharing be-
tween individuals, attached to a surface, at the level of single cells by using
fluorescent microscopy, and experimentally tested the physical boundaries of
pyoverdine sharing (chapter 5). We found that even in highly viscous envi-
ronments, pyoverdine is publically shared over a considerable distance. These
findings validate the assumption that pyoverdine is cooperatively shared, even
in viscous environments, such as experienced in infections, and therefore in-
dicates that anti-virulence treatments targeting pyoverdine (e.g. via gallium),
could indeed be evolution proof.
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1.6 Zusammenfassung
Opportunistische Erreger wie Pseudomonas aeruginosa entwickeln stetig Resisten-
zen gegen eine Vielzahl von Antibiotika und bedrohen immer öfter die Gesund-
heit von Patienten. Deshalb bedarf es dringend neuer Ansätze, mit denen wir
solche multi-resistenten Erreger bekämpfen können. Eine Möglichkeit wäre,
anstatt essentielle Zellmechanismen anzugreifen, Virulenzfaktoren direkt mit
sogenannten Anti-Virulenzmitteln zu inhibieren. Man geht davon aus, dass
solche Mittel einen geringeren Selektionsdruck auf Bakterien ausüben und des-
wegen weniger Resistenzen hervorrufen sollten. In dieser Arbeit wollen wir
diesen Ansatz weiter entwickeln und schlagen vor Virulenzfaktoren zu inhi-
bieren, welche sekretiert und zwischen Individuen kooperativ geteilt werden.
Wenn Erreger einen Wirt infizieren wollen, müssen viele von ihnen kooperieren,
was oft durch die Sekretion von kollektiv geteilten Virulenzfaktoren geschieht.
Kooperation kann jedoch von Individuen ausgenutzt werden, welche die Vor-
teile von kooperativem Verhalten genießen, ohne sich aber daran zu beteiligen,
sogenannte "Cheaters". Indem ein kooperativ geteilter Virulenzfaktor inhibiert
wird, verwandelt sich die Kolonie in phänotypische "Cheaters", welche jeden
ausnutzen werden, der wieder zu kooperieren beginnt (indem er z.B. resistent
wird) und folglich sollte Resistenz gegenselektioniert werden. Solch ein Mittel
könnte daher in der Tat evolutionär robust sein.
Diesen Ansatz haben wir anhand des kooperativ geteilten Virulenzfaktors Py-
overdin untersucht. Pyoverdin ist das primäre Siderophor von P. aeruginosa,
welches unter starker Eisenlimitierung sekretiert wird, um eine ausreichende
Versorgung mit diesem essentiellen Nährstoff sicher zu stellen. So trägt es
beispielsweise zum Wachstum von P. aeruginosa in Wirten bei. In Kapitel 3
haben wir einen vielversprechenden Kandidaten für ein evolutionär robustes
Anti-Virulenzmittel getestet. Das Übergangsmetall Gallium Pyoverdine und
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reduzierte in unseren Versuchen mit Insekten die Virulenz von P. aeruginosa
in der Tat sehr effektiv. Außerdem ist es nach einem Evolutionsexperiment
weiterhin gegen P. aeruginosa wirksam, wohingegen Resistenzen gegen konven-
tionelle Antibiotika schnell aufkommen.
Als nächstes haben wir untersucht, wie sich eine solche Manipulation der Ver-
fügbarkeit des Virulenzfaktors, auf den Erreger, sein genetisches regulatorisches
Netzwerk und den Wirt auswirkt (Kapitel 4). Wir haben komplexe Beziehun-
gen zwischen diesen Variablen festgestellt. Während die Verbindung zwis-
chen Virulenzfaktor-Verfügbarkeit und Virulenz positiv war, korrelierte die Py-
overdin-Verfügbarkeit nicht monoton mit dem Wachstum des Erregers inner-
halb des Wirts. Zusätzlich beeinflusste die Virulenzfaktorverfügbarkeit andere
Virulenzfaktoren, die mit Pyoverdin regulatorisch verbunden sind, sowie den
Wirt. Diese Ergebnisse zeigen die Notwendigkeit auf, die Konsequenzen von
Anti-Virulenzmitteln genau zu untersuchen, um einen wirksamen Ansatz zu
finden, dessen Effekte sich gut vorhersagen lassen.
Das Konzept von evolutionär robusten Anti-Virulenzmitteln beruht unter an-
derem auf der Annahme, dass der inhibierte Virulenzfaktor Pyoverdine, kollek-
tiv geteilt wird. Zwar wurde Kooperation mit Pyoverdine im letzten Jahrzehnt
detailliert untersucht, aber fast alle Studien beinhalten Experimente auf Popu-
lationsebene. Allerdings weiß man bisher wenig darüber, inwieweit die Ergeb-
nisse solcher Experimente sich auf Infektionen übertragen lassen. Dort kann
die Zellzahl sehr gering sein und Bakterien kooperieren im Bereich von eini-
gen Mikrometern. Unter diesen Bedingungen ist möglicherweise die Diffusion
des geteilten Guts stark limitiert. Deswegen haben wir mithilfe eines Fluo-
reszenzmikroskops die Pyoverdine-Kooperation auf Einzelzellebene untersucht
und deren physikalischen Grenzen experimentell ausgelotet (Kapitel 5). Wir
fanden heraus, dass Pyoverdine unter viskosen Bedingungen über eine größere
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Distanz geteilt wird. Diese Ergebnisse validieren die Annahme, dass Pyover-
dine auch unter viskosen Bedingungen geteilt wird, und dass Anti-Virulenzmit-
tel, die Pyoverdine inhibieren (wie z.B. Gallium), tatsächlich evolutionär robust
sein könnten.
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2 Introduction
Introduction
CHAPTER 2
It is not difficult to make microbes resistant to penicillin in
the laboratory by exposing them to concentrations not
sufficient to kill them, and the same thing has occasionally
happened in the body. The time may come when penicillin
can be bought by anyone in the shops. Then there is the
danger that the ignorant man may easily underdose himself
and by exposing his microbes to non-lethal quantities of the
drug make them resistant.
Alexander Flemming (1945)
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2.1 Cooperation in Bacteria
2.1 Cooperation in Bacteria
Bacteria are highly social organisms, which deploy cooperative behaviours to
overcome nutrient starvation, reproduce or infect a host. For instance, bacteria
cooperate when they form biofilms, control community-wide phenotypes via
quorum sensing, or when they secrete shareable compounds such as proteases
and siderophores [1–5].
In biofilms, bacteria live together in a matrix of secreted extracellular polymeric
substances to protect themselves from external influences, such as antibiotics
[3, 6–8]. Biofilms are mainly composed of extracellular DNA, polypeptides and
exopolysaccharides [9]. Biofilm-formation is thought to require a high degree
of cooperation, since all members of the community engage in the costly secre-
tion of these extracellular polymeric substances [3]. The protective effect of a
biofilm (e.g. protection from antibiotic treatment [8]) is, however, beneficial for
every member of the community and therefore, biofilm formation is seen as a
cooperative trait [10].
Two of the most studied cooperative behaviours in bacteria are quorum sens-
ing (QS), a communication tool for bacteria to regulate community wide phe-
notypes [11–18], and the production and secretion of siderophores [4, 19–24].
Siderophores are secreted, secondary metabolites with a very high affinity for
iron, an essential but simultaneously severely limited nutrient in most environ-
ments, including hosts [25]. Since these traits (QS and siderophore secretion)
are of particular relevance for this thesis, they will be discussed separately in
section 2.2 and 2.3.
Bacterial cooperation can have a severe impact on the health of patients, since
it often gives pathogens the necessary means to infect and spread within a host
and to endure antibiotic treatment (e.g. biofilms) [17, 26–29]. For instance, 65-
80% of all bacterial infections in humans are linked to biofilms and are therefore
associated with high rates of antibiotic resistance [30–32]. In infections Vibrio
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cholerae and P. aeruginosa use quorum sensing to control expression of virulence
factors [33, 34]. Moreover, the siderophores of P. aeruginosa are also virulence
factors, facilitating growth of the pathogen in infections [11, 16, 19, 33–38].
2.1.1 Bacterial Cooperation and the Problem of Cheating
Bacterial cooperation often relies on secreted factors that generate benefits for
all members of the community, so called public goods [39]. While coopera-
tion is a crucial part of the bacterial life, it is at the risk of being exploited
by non-cooperating individuals, which readily evolve, and reap the benefits
from cooperation without contributing to its costs. In the literature, they are
referred to as cheaters [4, 19, 39–44]. By not contributing to a costly coopera-
tive behaviour, these cheaters can allocate more resources into growth and are
therefore favoured by natural selection [44–46]. This leaves us with the central
question: if cooperation is seemingly not favoured by natural selection, why is
cooperation still a ubiquitous feature in the bacterial world [47]? There have to
be mechanisms that stabilizes bacterial cooperation in the presence of cheating
individuals and indeed such mechanisms have been described (for a more de-
tailed discussion see chapter 5 and [5]).
For example, the viscosity of the environment is predicted to greatly modulate
the success of cooperation [48–53]. When viscosity is high, diffusion rate of
public goods and therefore shareability is reduced. Hence, with increasing vis-
cosity, the benefit for cheaters is reduced [53]. Viscosity can reduce the social
aspect (sharing and cheating) of pyoverdine cooperation, but it can, however,
not be abolished [54]. Additionally, molecular and regulatory properties of the
cooperative trait can also help to maintain cooperation [43, 55]. By fine-tuning
the regulation of siderophore production (see section 2.3.3), combined with the
ability of P. aeruginosa to recycle and reuse its siderophores multiple times, the
molecular and regulatory properties can shape the selection for siderophore-
cooperation by maximizing the efficiency of siderophore production [53, 56, 57].
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2.2 Quorum Sensing
2.2 Quorum Sensing
Quorum sensing (QS) is one of the best studied cooperative behaviours in bac-
teria. QS is a communication tool for bacteria to coordinate population wide
phenotypes and has first been discovered in the marine bacterium Vibrio fischeri
in 1977 [58–60]. Since then QS has been investigated thoroughly on the social,
mechanistic and genetic level [61–66]. Although the genetic components and
regulatory pathways differ between species, the principle of QS is similar in
quorum-sensing bacteria [67–70]. Cells secret small signalling molecules into
the environment, which can bind to specific receptors. When cells proliferate,
signal molecules get more abundant and more molecules bind to the receptor.
When the signal reaches a threshold, QS-controlled genes are up- or downreg-
ulated [60, 71]. QS is a cooperative trait, helping the community to optimally
adapt to an environment and to regulate their phenotype [72]. QS cheaters,
which either do not produce the signal, or are blind to it, can be observed regu-
larly [73–75].
QS can control a variety of traits. In Streptococcus pneumoniae, QS acts like an on-
off switch, facilitating the switch to competence (ability to take up exogenous
DNA) and a fast reversion to the original behaviour [71]. In Bacillus subtilis two
antagonistically working QS-systems allow to choose between two mutually
excluding lifestyles (being competent or sporulation) [76, 77].
Quorum Sensing and Virulence
QS often contributes to the virulence of pathogens [15]. For example, V. cholerae
uses its QS-system to control expression of virulence factors. It promotes vir-
ulence factor production when cell numbers are low and downregulates viru-
lence, when signalling molecules get more abundant (due to growth) [11, 34,
35]. In P. aeruginosa, QS controls the expression and secretion of virulence fac-
tors (among other traits) in later growth phases. Under the control of QS are:
18
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proteases, like LasA and LasB [36], Exotoxin A (a toxin inhibiting elongation
factor-2 in eukaryotic cells), pyocyanin and hydrogen cyanide [16]. P. aerugi-
nosa requires QS in order to infect and colonize cystic fibrosis (CF) lungs [33].
2.3 Siderophores
Siderophores are small, secondary metabolites secreted by microbes to over-
come iron starvation in environments where this essential nutrient is limited
[25]. This is usually the case under physiological conditions, where iron is
present in its insoluble ferric form or within a host, where ferric iron is ac-
tively withheld by the immune system to hinder bacterial growth [20, 25, 56,
78]. To date more than 500 different siderophores have been described in bacte-
ria, yeasts and fungi [25]. Siderophores have a high stability constant1 range (Ks
= 1022 to 1050) and can sequester iron from various sources like the iron binding
protein transferrin [79].
2.3.1 The Siderophores of Pseudomonas aeruginosa
P. aeruginosa is capable of producing two different siderophores, namely py-
overdine and pyochelin [56, 80], with pyoverdine being the dominant sidero-
phore system, as its affinity to iron (K f = 1024 M−1) [80] is much higher than
the one of pyochelin (K f = 105 M−1)2 [56]. Other bacteria also have multiple si-
derophore systems. For example, Escherichia coli can produce enterobactin [81]
and aerobactin [82, 83], while Burkholderia cenocepacia secrets ornibactin and py-
ochelin [84–86]. In bacteria multiple (sometimes redundant) systems are not
uncommon, but it is still discussed why bacteria possess multiple siderophore
1The stability constant Ks measures the strength of the interaction between two reagents, form-
ing a complex.
2The binding constant K f describes the affinity between a ligand and a protein.
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systems. For P. aeruginosa it was suggested that pyochelin, since it is metabol-
ically cheaper, is predominantly used in environments where iron limitation is
less severe [87].
Once secreted, pyoverdine can be taken up by any cell with a compatible recep-
tor and therefore it is a cooperative trait. Pyoverdine producing individuals can
be exploited by non-producers. Such pyoverdine non-producing individuals
readily evolve under shaken conditions [4, 5, 88], within hosts [19, 89, 90] and
in the environment (Butaite E., Wyder S., Baumgartner M. and Kümmerli R.,
2017, accepted). These non-producers benefit from the pyoverdine produced by
others, without paying their share and thus they save resources. These cheaters
can outcompete cooperating strains [4, 40, 53, 91].
2.3.2 Pyoverdine and Virulence
In infections iron is actively withheld by immune system to deprive bacteria
of this essential nutrient. It is bound to iron binding proteins like transferrin,
lactoferrin or heme3, but pyoverdine can scavenge iron from these proteins and
is therefore secreted by P. aeruginosa to acquire sufficient quantities of iron [23,
25, 92–94]. Pyoverdine is an important virulence factor in acute infections, since
pyoverdine deficient strains display reduced levels of virulence in various ani-
mal models [22, 23, 37, 94–100]. However, in chronic infections the ability of P.
aeruginosa to produce pyoverdine is often reduced or lost [98, 101, 102].
Anderesen et al. [90] suggest that the loss of pyoverdine in chronic infections
is not due to adaptation to the host, but caused by social dynamics. Pyover-
dine non-producer thrive on the pyoverdine produced by others, and eventu-
ally outcompete pyoverdine producers [90]. This hypothesis is supported by
3Hemes are a group of iron carrying cofactors, most commonly recognized in hemoglobin.
Among other functions, they are responsible for the transportation of diatomic gases, where
the iron acts as a electron acceptor.
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the fact, that these pyoverdine non-producer retain their ability to express the
pyoverdine receptor. Moreover, these cells upregulate the less effective heme
uptake system to compensate for the loss of pyoverdine [103]. But, since these
mutations (loss of pyoverdine and upregulation of heme uptake systems) hap-
pen on a timescale of years, they might not be causally linked. Furthermore,
this hypothesis assumes that pyoverdine is freely diffusing within the infected
compartments, a question we tackle in chapter 5. Therefore, more thorough ex-
perimental examination is necessary to validate this hypothesis.
Both, pyoverdine and pyochelin are important in infections [23] (details in sec-
tion 2.3.2), this thesis, however, solely focuses on pyoverdine.
Pyoverdine Facilitates Expression of Virulence Factors
Pyoverdine has a double role in infections. It is an iron chelator, but it can also
act as a signalling molecule for virulence factors [21, 103, 104]. The pyoverdine
regulator PvdS (see section 2.3.3) controls (directly or partially) the expression
of two other virulence factors, namely Protease IV and Exotoxin A [16, 21, 105–
107]. Protease IV (piv) is directly controlled by PvdS [106] and upregulation of
pyoverdine could simultaneously lead to an increased expression of Protease
IV. This protease might work synergistically with pyoverdine, by cleaving iron-
loaded proteins (e.g. transferrin) and therefore freeing up iron, which becomes
available for pyoverdine driven uptake [106].
Furthermore, the pyoverdine regulator (PvdS) partially controls the transcrip-
tional regulator ToxR, which directly regulates the expression of Exotoxin A
(ETA) [21, 105]. ToxR has a second promoter-site that is likely responding to QS
[16]. Other factors influencing expression of ETA are cation concentration, tem-
perature and oxygen levels [108–110]. ETA is the most toxic virulence factor in P.
aeruginosa inhibiting the eukaryotic elongation factor-2 and thereby causing cell
death [111, 112]. The regulatory link between pyoverdine, ETA and Protease IV
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suggest that iron depletion plays a role in their expression. The functional role
of this link is, however, still obscure.
2.3.3 Regulation of Pyoverdine-Expression
Pyoverdine is a metabolically costly metabolite and therefore needs precise reg-
ulation to optimize costs and benefits of its production. Its regulation involves
negative and positive feedback loops (see figure 1) and is governed by two cen-
tral regulators, namely FUR (Ferric Uptake Regulator) and the alternative (ex-
tracytoplasmic4) sigma factor PvdS [56]. If iron levels in the cytoplasm are suf-
ficient, FUR builds a complex with Fe2+, which then binds to the pvdS-promoter
site, thereby inhibiting its transcription. When iron gets scarce, the Fe-FUR com-
plex is dissolved and can no longer inhibit transcription of PvdS. Depending on
growth phase, 582 to 720 copies of PvdS are present in the cytoplasm [113, 115].
PvdS in turn, promotes the expression of pyoverdine, which is produced in the
cytoplasm (non-ribosomal peptide synthesis) and maturated in the periplasmic
space [116, 117]. Pyoverdine is subsequently secreted by an ATP depended ef-
flux pump, consisting of an inner membrane protein (pvdT), a periplasmic adap-
tor protein (pvdR) and outer membrane protein (opmQ) with a β-barrel domain
inserted in the outer membrane and a large periplasmic extension [118]. This
efflux pump secrets newly synthesized pyoverdine, as well as pyoverdine that
was previously taken up by the cell [118]. Active uptake of ferri-pyoverdine
is followed by transport into the periplasmic space via a TonB system5. In the
periplasm, iron is released from pyoverdine by reduction from Fe3+ to Fe2+ and
transported into the cytoplasm, while pyoverdine is repeatedly secreted [56].
4Extracytoplasmic sigma factors usually react to environmental cues, governing expression of
extracytoplasmic functions [113, 114].
5TonB-dependent transporters are outer membrane proteins that bind and transport e.g. iron
loaded siderophores, which requires energy in the form of proton motive force [119].
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Figure 1: Scheme of the pyoverdine regulation pathway. The ferri-pyoverdine complex binds to the
specific receptor FpvA, transmitting a signal through the cell membrane, promoting transcription of
PvdS (via FpvR) and therefore the transcription of pyoverdine. Additionally, it can promote production
of piv (Protease IV) and ptxR (increases toxA expression by four to fivefold [108]). Additionally, PvdS
can regulated toxR, the regulator of ETA (pathway not shown in this figure). Figure from [104].
Since pyoverdine is stable and functional over (at least) 48 hours, pyoverdine
recycling reduces the costs of pyoverdine production [43].
Uptake of Iron Loaded Pyoverdine Triggers Pyoverdine Production
FpvR is an anti-sigma factor that, in the absence of pyoverdine, directs PvdS into
proteolytic pathway, therefore reducing pyoverdine production [113]. Upon
binding of iron loaded pyoverdine (ferri-pyoverdine) to the specific pyover-
dine receptor FpvA, a signal is transmitted through the cell membrane. The
FpvA-signal suppresses the anti-sigma activity of FpvR, triggering the activa-
tion of PvdS and the release of membrane-bound PvdS to positively regulate
expression of pyoverdine [56, 104, 120, 121]. Additionally, FpvA promotes the
transcription of the extracytoplasmic sigma-factor FpvI, which upregulates the
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production of the pyoverdine receptor (figure 1) [21, 56]. This regulation cas-
cade is only triggered by the binding of iron-loaded pyoverdine [56, 104, 113].
Consequently, upon binding of iron-loaded pyoverdine, the expression of py-
overdine and its receptor is upregulated until iron supply is sufficient, which
leads to a negative feedback by FUR, inhibiting pvdS-transcription, eventually
causing a shutdown of pyoverdine production. Thus, pyoverdine positively
regulates its own and the expression of its receptor. When iron loaded pyover-
dine binds to the receptor, it can cause a cascade of transcriptional and regula-
tory changes (pyoverdine cluster, pyoverdine receptor, Protease IV and ETA),
ultimately contributing to the virulence of P. aeruginosa [56].
2.4 New Approaches to Fight Multi-Drug-Resistant
Pathogens
2.4.1 The Problem of Antibiotic Resistance
Alexander Fleming, who discovered penicillin in 1928, predicted in his No-
bel lecture (1945) that bacteria can develop resistance to penicillin quiet easily
(Alexander Flemming: Nobel Lecture, December 1945 6). Over 60 years later,
we realised that bacteria not only develop resistance to penicillin, but to all
classes of antibiotics (figure 2), even to antibiotics where resistance was thought
to be impossible (e.g. vancomycin [122, 123] and to last resort antibiotics like
carbapenems [124]. The use of antibiotics has become unsustainable and physi-
cians are running out of antibiotics they could use to cure infections caused by
multi-resistant bacteria [125]. It is often postulated that a limitation of antibiotic
usage will help to maintain their efficacy [126–129]. Though it is crucial to use
6https://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/
fleming-lecture.pdf, accessed 17.03.2017, 13:30
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Figure 2: Time line for different classes of antibiotics from introduction to loss of efficacy. The bars
indicate the introduction and subsequent evolution of resistance. The faded region denotes the time
between the first report of resistance to the complete loss of efficacy. Adapted from [137]. Original data
from [138].
antibiotics efficiently, we may have passed the threshold where solely limiting
usage will improve the situation [130]. While antibiotic resistance becomes an
increasing risk for public health, the development and release of new antibiotic
agents has almost stalled [131, 132]. Incentives to develop new classes of antibi-
otics are low due to the short expected lifespan [133]. Support for development
of new classes of antibiotics is crucial, but every new agent, that is based on the
principal of killing bacteria or hindering their growth, is potentially doomed to
become ineffective over time as evidenced by the rapid rise and spread of antibi-
otic resistance by de-novo acquiring or horizontal gene transfer [122, 123, 134–
136]. Eventually nosocomial pathogens like Acinetobacter baumannii, P. aerug-
inosa or Enterobacteriaceae (which have been declared by the WHO, to be the
most dangerous bacterial pathogens7) will acquire resistance.
It is apparent that we need new concepts to fight infections, caused by multi-
7http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_
WHO.pdf, accessed 09.03.2016, 10:30
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resistant bacteria. One strategy is to improve hygiene standards in hospitals and
to test disease causing pathogens for their susceptibility to antibiotics to ensure
that the administration of antibiotics is as effective as possible [139]. Further-
more, we could try to find novel strategies how to get along with the drugs we
have at our disposal. Such approaches involve mixing (combination therapies)
and cycling of drugs (alternating antibiotics). It is believed that bacteria should
have difficulties to simultaneously develop resistance to two or more antibi-
otics with different modes of action [140, 141]. But combination therapies and
antibiotic cycling are at the risk of becoming ineffective if the wrong antibiotics
are applied, since bacteria could activate mechanisms that confer resistance to
multiple drugs.
2.4.2 Anti-Virulence Treatments
The reason why bacteria develop resistance is simply natural selection, which
favours only those strains that are capable of surviving the deleterious effects
of antibiotics [142]. Hence, the high rate of resistance in nosocomial pathogens
is owned to the high killing potential of antimicrobial agents [134]. Taking this
into consideration, new therapeutic strategies should involve approaches that
escape the strong selection pressure of antibiotics, thereby minimizing the evo-
lutionary response [134, 142]. It was suggested that, instead of targeting vital
cell mechanism, we could reduce the virulence of pathogens by disarming them
[143–146]. Such treatments (figure 3) have been coined with the term "anti-
virulence treatments" and currently there is a lot of interests to find agents that
target bacterial virulence factors [18, 137, 142, 144, 145, 147–149]. Additionally,
it was proposed that such anti-virulence treatments can become evolution proof
(for details see section 2.5) [96, 142]. A treatment is evolution proof, if bacteria
cannot develop resistance to it.
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Figure 3: (A) In a classical infection, bacteria adhere to host tissue, using their flagella and pilli. They
then secrete quorum-sensing molecules (red dots) to coordinated virulence factor (green dots) expression
such as siderophores, tissue degrading enzymes or proteases. All named traits can be targets for poten-
tial anti-virulence treatments. (B) They could prevent adhesion, (C) silent microbial communication
by quenching quorum sensing molecules (quorum quenching), (D) or inhibit/quench bacterial toxins,
proteases or other virulence factors. Image credits: [142]
Examples of Anti-Virulence Treatments
An example for an anti-virulence treatment are phosphonosulphonates, which
reduce the virulence of Staphylococcus aureus. Phosphonosulphonates inhibit the
production of staphyloxanthin, a bacterial anti-oxidant pigment that normally
protects S. aureus from neutrophil-based killing and by inhibiting it, the cells
become exposed to the immune system [150].
In another approach, Henry and colleagues elegantly inhibit toxins of the CDC-
family (cholesterol-dependent cytolysins), by constructing artificial liposomes
[151]. These toxins are produced by a wide range of gram positive pathogens,
including Clostridium, Streptococcus, Listeria and Bacillus [152], in order to form
pores into the cell wall of host cells [151], thereby facilitating the infection. They
constructed individual artificial liposomes, which could effectively bind vari-
ous toxins during infections. By using a mixture of these liposomes, the authors
were able to inhibit various toxins produced by staphylococcal pathogens and
treat, otherwise fatal infections in a mouse model [151].
In cystic fibrosis infections, P. aeruginosa forms biolfilms, which are associated
with antibiotic resistance and protection from the immune system [30, 153, 154].
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Consequently, biofilms are an attractive target for treatment of P. aeruginosa
and other biolfilm making pathogens [155–160]. These "anti-biofilm"-treatments
could either work by interfering with biofilm-regulation or by destroying the
exopolysaccharides of the biolfilm. By doing so, bacteria are more accessible to
the immune system and antibiotic treatment and infections can be cleared more
easily [161].
Moreover, we can inhibit siderophores of pathogens to undermine iron supply
of the bacteria and consequently reducing their pathogenicity. In chapter 3 we
propose gallium as an anti-virulence treatment that inhibits the siderophore of
P. aeruginosa [162, 163]. More examples for potential targets of anti-virulence
treatments can be found in table 2.2 at the end of this chapter.
Reducing Virulence by Interfering with Quorum Sensing
Another attractive target is the QS system of pathogens. Manipulating QS would
reduce expression of multiple virulence factors simultaneously. In V. cholerae
QS controls the expression of virulence factors at early stages of the infection.
When the QS-signal increases (due to growth), virulence factors production is
suppressed (see section 2.2). Addition of QS-signalling molecules could there-
fore promote a non-virulent state [164].
In P. aeruginosa, QS regulates the expression of multiple virulence factors like
proteases, pyocyanin, Exotoxin A, etc. [16, 36]. By silencing QS, expression
of these virulence factors would be abolished, making P. aeruginosa infections
more benign. This approach has been described as “quorum quenching”. The
quorum sensing process is basically divided into three steps: (i) production of
the signal, (ii) accumulation of the signal and (iii) binding to the receptor. Quo-
rum quenching compounds can interfere with all three steps. For example one
could attempt to degrade the signalling molecules extracellularly. Many bac-
teria and other organisms secrete metabolites to degrade signalling molecules
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from other species [165–168] and also our immune system is capable of destroy-
ing signalling molecules produced by the LasR-system of P. aeruginosa [169].
Three categories of enzymes are known to be able to degrade AHLs (produced
by P. aeruginosa): acylases, lactonaes, oxidoreductases. Each of them has been
shown to target quorum sensing molecules produced by the LasR- and RhlR-
system of P. aeruginosa [59]. Moreover we can make use of e.g. furanones, which
interferer with receptor binding of QS-signalling molecules, thereby inhibiting
accumulation of the signal and consequently the expression of QS-controlled
traits [170–173].
2.4.3 The Evolution of Resistance to Anti-Virulence
Treatments
Antibiotics often require uptake of the drug by the cell. Among other mecha-
nisms, multidrug efflux pumps are part of the innate or acquired resistance to
antibiotics and are upregulated in the presence of antibiotics [174–181]. Put sim-
ply, everything which enters the cells could be pumped out using such efflux
pumps. By administering antibiotics, the cells are exposed to strong selection
pressure and e.g. upregulating the efflux pump results in strong positive evo-
lutionary feedback, namely the survival of the cell [144]. The same is true for
treatments that target virulence factors within cells. Resistance can be acquired
by classical multi drug resistance mechanisms (table 2.1).
Anti-virulence treatments aim to reduce selection pressure on bacterial cells,
making resistance less likely. But is this really the case? Phosphonosulphonates
(section 2.4.2) expose S. aureus to the immune system and therefore to the re-
moval from the infection site. Hence, they impose a strong selection pressure
on the bacteria, making resistance more likely [142]. Furthermore, phospho-
nosulphonates have to enter the cell, making it easier for S. aureus to develop
resistance.
In studies [182] and [183] the resistance to quorum quenching compounds (fura-
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Routes to resistance
Drug must
enter the cell
Drug works
outside the cell
Pyoverdine is inhibited
by gallium
Preventing drug entry yes no no
Increasing drug efflux yes no no
Target modification yes yes Yes
Drug degradation yes yes no
Switch to alternative
virulence factors
yes yes yes
Table 2.1: Possible routes to resistance for treatments that target virulence factors within the cell and
outside of the cell and for gallium, the anti-virulence treatment described in chapter 3.
nones) is described. Furanones block the receptor for quorum sensing molecules
within the cell (AHLs bind to the receptor intracellularily to form a multimere
that can bind DNA to regulate genes [33, 184]). Hence they could be subjected
to resistance mechanisms like efflux pumps. Moreover, resistance to enzymes
that inhibit AHLs outside of the cell or disrupt biofilms, could be acquired by
extracellular degradation of these compounds. Consequently, in terms of resis-
tance, such agents are more like antibiotics and therefore may be equally prone
to resistance.
The anti-virulence agent we used in chapter 3 also reduces growth of the patho-
gen and thereby reduces virulence [96]. However, Garcia-Contreras et al. (2013)
claim to find resistance to gallium (the anti-virulence agent we used in) [185]. If
resistance to anti-virulence agents is seemingly possible, how can we than make
anti-virulence agents evolution proof?
2.5 Evolution Proof Drugs
Anti-virulence treatments are predicted to be evolution proof if (i) they have
marginal fitness effects on the pathogen, (ii) target a secreted virulence factor
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and (iii) the virulence factor is cooperatively shared between individuals [142].
First, inhibiting a virulence factor with marginal fitness effects reduces the evo-
lutionary pressure to become resistant [142]. Second, by targeting a secreted
virulence we can circumvent some resistance mechanisms (see table 2.1; details
in section 2.5.1) [186]. And third, by targeting a cooperatively shared virulence
factor, we can disconnect the rise of a resistance mutant and its spread in the
community (for details see 2.5.2). Hence, observing the rise of a resistant phe-
notype (as in [185]) does not automatically imply that resistance will spread
within the community [187].
2.5.1 Targeting a Secreted Virulence Factor
So far, the term virulence factor was used as a generic term for factors which
facilitate infections e.g. help the bacteria to overcome the host’s immune re-
sponse or to proliferate at the infection site. However, it is crucial to distinguish
between virulence factors that are associated with the cell and virulence fac-
tors which are secreted into the environment. Treatments that inhibit secreted
virulence factors do not enter the cell, hence they can escape some resistance
mechanisms like efflux pumps or preventing drug entry (see table 2.1) [142].
In section 3 we quenched the virulence factor pyoverdine by using gallium. Py-
overdine cannot distinguish between iron and gallium, but binds preferentially
to the later, rendering it useless as an iron delivery system [162, 163]. By quench-
ing pyoverdine we inhibit a secreted virulence factor and potential routes to re-
sistance are limited (table 2.1). However, as described in [185], individual cells
can become resistant to gallium.
Consequently, treatments that target secreted virulence factors minimize, but
do not abolish the possibility of resistance development and are therefore not
evolution proof.
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2.5.2 Targeting a Cooperatively Shared Virulence Factor
It is crucial to distinguish between virulence factors that benefit only the pro-
ducer and virulence factors that generate benefits for all cells in a collective
[144]. Many bacterial virulence factors belong to the later class [188]. Shared
virulence factors, scavenge nutrients (e.g. siderophores) and digest or liberate
resources (e.g. proteases, elastases) to promote growth at the infection site [5, 22,
89, 188, 189]. The production and secretion of these virulence factors is costly,
but benefits all compatible cells in the vicinity. By inhibiting such a virulence
factor, the pathogen becomes a phenotypic non-producer and thus will exploit
any resistant phenotype, e.g. by resuming cooperation (see section 2.1.1) [190].
Hence, this resistant phenotype would not be favoured by natural selection and
cannot spread. Although anti-virulence treatments aim to minimize the chance
that bacteria develop resistance, it is possible that a resistant phenotype arises
(as evident in [185]). But by targeting a collectively shared virulence factor, we
can exploit social dynamics and create an environment where resistance is se-
lected against, hence the anti-virulence agent can become evolution proof.
In our previously mentioned study (chapter 3), we quenched the siderophore
pyoverdine by using gallium. We argued that the likelihood of resistance to gal-
lium is low and that gallium might be a good candidate for an evolution proof
drug [191]. In chapter 3 (table 1) we discuss in detail potential resistance mech-
anisms against gallium and if these mechanisms can facilitated resistance of the
community.
2.6 Aims of this Thesis
In this thesis, I tackled three objectives. In the first chapter (3), we will test
the anti-virulence agent gallium for its potential to reduce the virulence of P.
aeruginosa. Gallium inhibits pyoverdine irreversibly, reducing iron uptake and
therefore the potential of P. aeruginosa to cause damage to the host. To test our
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hypothesis, we will use an insect model and record the survival of larvae in the
presence or absence of gallium. Moreover, we propose that gallium is a promis-
ing candidate for an evolution proof treatment and therefore we will assess its
potential for resistance development compared to conventional antibiotics.
In chapter (4) we hypothesise that administration of gallium can have complex
consequences for the pathogen, its regulatory network and the host. To test
our hypothesis, we will use the same insect model as above and vary the avail-
ability of the virulence factor pyoverdine. We will assess virulence, pathogenic
growth (in-vivo), expression of virulence factors (which are regulatorily linked
to pyoverdine) and the hosts response.
In the third part of the thesis, I will address a different question. Bacterial co-
operation has be thoroughly investigated over the last decade, but mainly in
liquid cultures across millions of cells. Predictions derived from such experi-
ments may have only limited significance for environments where diffusion of
public goods is reduced (higher viscosity) and cell number is strongly limited,
e.g. during infections. The objectives above, however, assume that under such
conditions, cooperation is a crucial part of pathogenicity. Therefore, we will
verify this assumption by studying cooperation of surface attached bacteria at
the level of single cells by using florescence microscopy. We will track the ef-
fect of cooperation when cell numbers and diffusivity of pyoverdine is severely
limited. By using fluorescent reporter strains, we aim to measure investment of
bacteria into pyoverdine production in the presence and absence of pyoverdine
non-producers. Moreover, by assessing the natural fluorescence of pyoverdine
in pyoverdine non-producers we want to investigate the shareability of pyover-
dine in highly structured environments. From experiments in batch culture we
know that pyoverdine cheating boosts growth of non-producer at the cost of
cooperating individuals. To establish the physical boundaries of pyoverdine
sharing, we will compete producers and non-producers and manipulate the dis-
tance between the competitors and the viscosity of environment.
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im
s
ofthis
T
hesis
Virulence Factor Role at Infection side Possible treatment
Siderophores Iron-scavenging molecules [27] gallium [96, 163]
Adhesion inhibitors Adhesion to other cells or surfaces sortase A inhibits adhesion of S.
aureus [192, 193]
Exopolysaccharide Providing structure for growth and
protection ([194, 195])
Inhibiting or destroying biofilms
e.g. [196]
Shiga toxins Breaking down host tissue [197] Urtoxatumab [198]
Proteases Extracellular protein digestion [199] NA
Bacterial toxins and toxin
co-regulated factors
Inflammation, releasing nutrients Artificial liposomes [151] and Vir-
satin [200]
Manipulating QS-systems Interfering with synthesis, accumula-
tion or receptor binding of singling
molecules
Overview in [59]
Table 2.2: List of potential targets for anti-virulence treatments and (if available) possible agents that inhibit these virulence factors.
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Dübendorf, Switzerland; 3Institute of Evolutionary Biology and Centre for Immunity, Infection and Evolution, University of
Edinburgh, West Mains Road, Ashworth Laboratories, Edinburgh EH9 3JT, UK
*Correspondence address. Institute of Plant Biology, University of Zürich, Winterthurerstrasse 190, 8057 Zürich,
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A B S T R A C T
Background and objectives: Conventional antibiotics select strongly for resistance and are consequently
losing efficacy worldwide. Extracellular quenching of shared virulence factors could represent a more
promising strategy because (i) it reduces the available routes to resistance (as extracellular action
precludes any mutations blocking a drug’s entry into cells or hastening its exit) and (ii) it weakens
selection for resistance, as fitness benefits to emergent mutants are diluted across all cells in a
cooperative collective. Here, we tested this hypothesis empirically.
Methodology: We used gallium to quench the iron-scavenging siderophores secreted and shared among
pathogenic Pseudomonas aeruginosa bacteria, and quantitatively monitored its effects on growth in vitro.
We assayed virulence in acute infections of caterpillar hosts (Galleria mellonella), and tracked resistance
emergence over time using experimental evolution.
Results: Gallium strongly inhibited bacterial growth in vitro, primarily via its siderophore quenching
activity. Moreover, bacterial siderophore production peaked at intermediate gallium concentrations,
indicating additional metabolic costs in this range. In vivo, gallium attenuated virulence and
growth—even more so than in infections with siderophore-deficient strains. Crucially, while resistance
soon evolved against conventional antibiotic treatments, gallium treatments retained their efficacy over
time.
Conclusions: Extracellular quenching of bacterial public goods could offer an effective and evolutionarily
robust control strategy.
K E Y W O R D S : antivirulence therapy; public good quenching; resistance; experimental evolution;
Pseudomonas
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INTRODUCTION
Like all organisms, pathogens acquire genetic mu-
tations, and, in time, even ‘pure’ cultures will inevit-
ably come to harbor mutant lineages. Such genetic
variability can make some pathogen variants less
sensitive to therapeutic interventions than others,
and under strong or sustained therapy, these resist-
ant variants will have a selective advantage and will
come to predominate over more susceptible vari-
ants. Consequently, the therapy will lose efficacy [1,
2]. To avoid this situation, we can try to prevent re-
sistant variants from arising and/or from spreading
[3]. To prevent resistance arising, we could attempt
to reduce mutation supply, through limiting effect-
ive population size or by employing interventions
with specialized modes of action where relatively
few ‘routes to resistance’ are possible. To prevent
spread, meanwhile, we must aim to minimize fitness
differences across individual pathogens. Killing
every individual, the conventional antibiotic strat-
egy, could certainly quash fitness evenly, but this is
difficult in practice and whenever incomplete gives
resistant pathogens a strong relative fitness advan-
tage. ‘Antivirulence’ treatments, meanwhile, osten-
sibly disarm but do not harm pathogens, such that
resistant variants should benefit little relative to sus-
ceptibles [4]. However, traits that affect virulence but
not fitness are rare, and the label ‘antivirulence’ is
used liberally, even for interventions that yield sub-
stantial fitness differences among pathogens [4]. A
final way to minimize fitness differences is to tar-
get pathogens’ collective traits, where costs and
benefits are widely shared. For instance, many viru-
lence-related bacterial exoproducts are also public
goods (PGs) [5]. Under PG-quenching therapy, any
mutations allowing PGs to build up again should
benefit both resistant and susceptible individuals
alike, which would hinder the spread of resistance
[1, 6–8].
To illustrate why this matters, let’s consider a
specific example. Quorum quenching (QQ), which
disrupts the cell-to-cell communication [quorum
sensing (QS)] [9] underlying a wide range of collect-
ively expressed virulence traits, is a PG-targeting
‘antivirulence’ therapy regarded as a promising
alternative to conventional bacteriocidal or bacterio-
static treatments [10, 11]. However, early enthusi-
asm for QQ has been tempered recently by reports
that bacteria can quite readily evolve resistance to
such treatments [12–14]. Set against our framework,
this is unsurprising: first, QQ interventions
frequently involve intracellular action, against which
many potential resistance-conferring adaptations
could arise (e.g. modified membrane properties to
block a drug’s entry into a cell, or upregulated efflux
pumps to hasten its exit [15]). Second, QS regulates
not only PGs but also certain essential private goods
[16], giving QQ resistants substantial personal bene-
fits over susceptibles—and therefore a means to
spread. For maximal evolutionary robustness, we
need therapies where resistance mutations are un-
likely to arise in the first place (e.g. extracellular ac-
tion restricts potential routes to resistance) and are
also unlikely to spread, because fitness differences
between resistant and susceptible pathogens are
minimized. The latter should be the case when col-
lective traits are targeted, because fitness conse-
quences are shared across many individuals. Of
course, the extent and evenness of this sharing will
depend on the relatedness and spatial structure
of the pathogen population and the diffusive
properties of the environment, and these factors
would also need to be considered during therapy
design [3].
In this study, we investigate—in a test case—the
hypothesis that extracellular PG quenching is an
effective and evolutionarily robust strategy for patho-
gen control. The PG trait we target is siderophores,
important exoproducts whose regulation is not linked
to any exclusively private goods. Siderophores are dif-
fusible molecules with a high affinity for ferric iron
(Fe3þ) and are secreted by most bacteria to scavenge
this important but generally bio-unavailable form of
iron from their environment or, in the case of patho-
gens, from their host’s own iron-chelating com-
pounds [17]. Once loaded with Fe3þ, siderophores
are taken up by producer cells—or other nearby indi-
viduals equipped with appropriate receptors—
stripped of their iron, and secreted once again into
the environment [18]. Although their primary function
may be to scavenge iron, siderophores also bind, with
varying success, several other metals [19, 20]. Among
these, gallium is the closest mimic of iron. Ga3þ and
Fe3þ ions have very similar ionic radii and binding
propensities but, crucially, while Fe3þ reduces readily,
Ga3þ does not [19]. Ga3þ therefore cannot replace
iron as a co-factor in redox-dependent enzymes. We
investigated the iron-mimicking effects of gallium on
pyoverdine, the primary siderophore of Pseudomonas
aeruginosa [21], a widespread opportunistic pathogen
with a broad host range and, in humans, the cause of
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notoriously persistent infections in immune-
compromised tissues, cystic fibrosis lungs and in as-
sociation with implanted devices [22]. Pyoverdine,
which plays an important role in such infections [23,
24], binds gallium at least as readily as iron, and gal-
lium-bound pyoverdine is of no use to iron-starved
cells [19, 20]. Thus, even without entering the cell,
gallium can reduce P. aeruginosa growth and biofilm
formation by quenching local stocks of secreted
pyoverdine and choking off iron supply [19, 25].
Below, we report our investigations into (i)
gallium’s in vitro interference with siderophore-
mediated iron uptake and consequent effects on
bacterial growth, (ii) gallium’s in vivo effects on viru-
lence and in-host bacterial growth and (iii) the
potential for bacteria to evolve resistance against
gallium treatment.
METHODOLOGY
Strains and media
Pseudomonas aeruginosa strains featured in our
experiments included the wild-type strain PAO1
(ATCC 15692), the siderophore knock-out mutants
PAO1pvdD and PAO1pvdDpchEF [26], provided
by P. Cornelis, Free University of Brussels, Belgium, as
well as versions of the above strains constitutively ex-
pressing GFP (PAO1-gfp, PAO1pvdD-gfp, chromo-
somal insertion: attTn7::ptac-gfp), and a version of
PAO1 with a pvdA-gfp reporter fusion (PAO1pvdA-gfp,
chromosomal insertion: attB::pvdA-gfp) [27], provided
by P. K. Singh, University of Washington, USA. We also
used the Rhl-quorum-sensing deficient mutant
PAO1rhlR, provided by S. P. Diggle, University of
Nottingham, UK. For overnight culturing, we used
Luria Bertani (LB) medium, while for experimental
assays we used CAA medium, supplemented with
FeCl3 where indicated to manipulate iron availability.
LB was obtained pre-mixed from Sigma-Aldrich,
Switzerland. Our standard CAA medium contained
5 g l1 casamino acids, 1.18 g l1 K2HPO4*3H2O,
0.25 g l1 MgSO4*7H2O, 100mg ml
1 human-apo
transferrin, 20 mM NaHCO3 and 25 mM HEPES buffer
(all from Sigma-Aldrich).
In vitro assays of growth and pyoverdine
production
Overnight LB cultures (37C, 180 rpm), washed and
standardized for cell density, were diluted to 104
then used to seed replicate cultures in CAA medium
supplemented with Ga(NO3)3 (such that final Ga
concentrations ranged from 0 to 200mM), as
well as complementary amounts of NaNO3 to bal-
ance nitrate levels across treatments, and 20 mM
FeCl3 where iron-replete conditions were required
(Fig. 1A). Growth assays were performed with 200ml
cultures in 96-well plates, for which optical density
(OD) was tracked over 24 h at 37C using a Tecan
Infinite M-200 plate reader (Tecan Group Ltd.,
Switzerland), with 15 min read intervals preceded
at each read by 10 s of agitation. To assay pyoverdine
production, we first grew PAO1pvdA-gfp in 2 ml CAA
static in 24-well plates in a 37C incubator for 24 h,
then centrifuged the cultures at 7000 rpm for 2 min
to pellet the cells. From each culture, 200 ml of super-
natant and, separately, the cell fraction resuspended
in 200ml 0.8% saline, were transferred to a new 96-
well plate and assayed for OD at 600 nm and fluor-
escence (GFP in cell fraction: exjem¼ 488j520 nm;
pyoverdine in supernatant: 400j460 nm) [28]. Both
fluorescence measures were standardized by OD
at 600 nm. In a series of side experiments, we
investigated potential biases associated with the
use of optical measures as proxies for pyoverdine
production (Supplementary Fig. S1). Data pre-
sented in Fig. 1B are corrected for these biases.
Experimental infections
Infection assays were performed with final instar
Galleria mellonella larvae, purchased from a local
supplier, standardized for mass and general condi-
tion and stored at 4C until use (within 3 days).
A Hamilton precision syringe was used to deliver
10ml inocula via a sterile 26s gauge needle
introduced sub-dermally to a surface-sterilized area
between the last pair of prolegs. Inoculations con-
tained Ga(NO3)3 diluted to different concentrations
in 0.8% saline, with complementary concentrations
of NaNO3, and, where specified, bacteria from over-
night LB cultures (37C, 180 rpm), standardized for
cell density and diluted such that each 10 ml inocula
contained 25 CFU (post hoc counts of 12 inocula
plated out to LB agar gave 95% CI of 19.41–31.76).
Specifically, we tested the following Ga(NO3)3 con-
centrations: 2.5, 10 and 50 mM (‘LOW’; pooled to-
gether since their resulting virulence curves were not
significantly different from one another), 500 mM
(‘MED’) and 2500 mM (‘HIGH’). Our ‘Gallium only’
treatment comprised various concentrations be-
tween 2.5 and 2500mM, which again we pooled
for statistical analyses because of similar effects
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on survival. Post-injection, larvae were placed indi-
vidually in randomly allocated wells of 24-well plates
and incubated at 37C. Survival was monitored
hourly between 10 and 24 h, and larvae were con-
sidered dead once they no longer responded to tact-
ile stimulation. Any larvae that began to pupate while
under observation or died within the first 10 h post-
injection (i.e. as a result of handling) were excluded
from analyses (n¼ 23, 3.6%). To assay in vivo bac-
terial growth, we prepared our inocula with strains
engineered to constitutively express GFP (see
above), having previously established that constitu-
tively expressed GFP signal could provide a reliable
correlate of bacterial density under the conditions
of this infection model (Supplementary Fig. S2). In
each of six separate experimental blocks, and at each
of four discrete timepoints, 3–4 randomly selected
larvae per treatment were flash-frozen in liquid N2
and manually powderized. Powdered larval hom-
ogenates were resuspended in 1 ml sterile H2O, vig-
orously shaken and then centrifuged at 7000 rpm for
2 min, whereafter the sample segregated into dis-
crete phases. About 200 ml of the water-soluble
liquid phase was extracted and assayed for GFP-
fluorescent signal relative to control replicates (sa-
line-injected larvae), using a Tecan Infinite M-200
plate reader. Given total larval volumes of 1 ml,
and assuming that 20% of this volume might be
hemolymph accessible to particles diffusing from a
single injection site during the course of an acute
infection, we estimate that inocula gallium concen-
trations of 2.5–2500mM would translate to in-host
gallium concentrations of roughly0.05 to50 mM.
Experimental evolution
We compared the growth inhibitory effects of gal-
lium versus the aminoglycoside, gentamicin (Gm),
and the fluoroquinolone, ciprofloxacin (Cp)—two of
several antibiotics recommended for clinical use
against P. aeruginosa [29]. Concentrations were
calibrated such that they reduced growth integrals
over the initial 24 h to 1/3 that of untreated PAO1
WT cultures under the same growth conditions.
For each of 12 days, a 96-well plate was prepared,
comprising replicate 198ml volumes of iron-limited
CAA medium supplemented, according to a
randomized layout scheme, with gallium, antibiotics
or an equivalent volume of saline (see key in Fig. 3 for
details of treatments used and their respective sam-
ple sizes). Day 1 cultures were initiated with 2ml ali-
quots of a 103 diluted overnight LB culture of PAO1
WT (37C, 180 rpm), while for subsequent days,
fresh plates were inoculated with 10 ml of undiluted
culture from the corresponding wells of the previous
day’s plate, directly after it completed its growth
cycle. Plates were incubated at 37C, and cell density
and pyoverdine fluorescence measures were re-
corded at 15 min intervals (with 10 s initial shaking)
using a Tecan Infinite M-200 plate reader.
Figure 1. Gallium affects P. aeruginosa’s in vitro growth and siderophore production. (A) Gallium suppresses growth particularly when pyoverdine is present, as
shown here by comparing conditions with and without its production. Symbols and bars indicate means and 95% CIs of integrals of spline curves fitted through
24 h growth trajectories (OD at 600 nm) of 12 replicate cultures. (B) Pyoverdine, assayed using complementary approaches, is in each case upregulated at
intermediate gallium concentrations. Symbols and error bars represent means and SEs of five replicates. Measures of pyoverdine from supernatant (filled circles)
or pvdA expression from cell fractions (open circles) are in each case scaled by cell density (OD at 600 nm).
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Endpoint phenotypic assays
Prior observations [30] and our own reasoning (see
Table 1) suggested that pyoverdine and pyocyanin
could both affect the costs and benefits of iron
uptake under gallium treatment. Anticipating that
the experimental evolution described above might
have induced changes in these traits, we performed
phenotypic assays to compare cultures of our ances-
tral PAO1 WT, its descendent lines experimentally
evolved in CAA with or without supplementa-
tion with 20 mM Ga, and also two knock-out mu-
tant strains which served as negative controls:
PAO1pvdD (deficient for pyoverdine production)
and PAO1rhlR (deficient for the Rhl-quorum-
sensing system which regulates pyocyanin produc-
tion [31]). Specifically, we inoculated 2 ml volumes of
growth medium (either LB or CAA) with 20ml of 103
diluted overnight LB culture and incubated at 37C
in static conditions. After 24 h, we measured OD
600, centrifuged at 7000 rpm for 2 min, then ex-
tracted 200ml aliquots of supernatant and assayed
these for growth (OD at 600 nm) and levels of
pyocyanin (using OD at 691 nm) [32] and pyoverdine
(fluorescence at 400j460 nm), using a Tecan Infinite
M-200 plate reader.
Statistical analyses
All analyses were performed using R 3.0.0 [33].
Spline curves were fitted to time course growth data
using the ‘grofit’ package [34]. Survival analyses were
performed using the Surv package [35]. Although in
the main text we compared survival curves using
parametric Weibull models, we also repeated all ana-
lyses using Cox proportional hazards regressions,
and obtained qualitatively comparable results in all
cases.
RESULTS
In in vitro assays, we found that gallium strongly in-
hibited bacterial growth, and that the inhibitory ef-
fects were mediated primarily via gallium’s
extracellular quenching activity and not because gal-
lium is toxic per se (Fig. 1A). When siderophores
were required and could be produced, increasing
gallium concentration was associated with a steep
decline in growth (slope ± SE of regression with
log10[Ga]: 0.435 ± 0.011, t¼38.04, P< 0.001).
In contrast, when siderophores were not required
and not produced, gallium only weakly affected
growth (slope ± SE: 0.067 ± 0.019, 95% CI for
drop¼ [2.91–15.86%]; difference in slopes
0.368 ± 0.022, F1,140¼ 276.41, P< 0.001)—particu-
larly over the range of concentrations up to and
including 50 mM, which correspond to the concen-
trations likely experienced in our in vivo experiments
(see below).
It has been suggested that as the benefit of
pyoverdine production drops, bacteria should grad-
ually scale back their investment in this trait [19].
On the other hand, it has also been shown that
pyoverdine production is upregulated in response
to more stringent iron limitation [28], as presumably
induced by gallium. Here, we saw a combination of
these two regulatory effects, with investment to re-
place quenched pyoverdine actually increasing from
low to intermediate gallium supplementation levels
and cessation becoming evident only at higher con-
centrations (Fig. 1B; ANOVA comparison of quad-
ratic versus linear fits: F1,36> 15, P< 0.001 in
each case).
Given our in vitro observations of gallium’s effects
on growth and pyoverdine production, we expected
it to affect virulence and bacterial fitness in vivo too.
We tested this in experimental infections of greater
waxmoth larvae (G. mellonella). Gallium-supple-
mented P. aeruginosa infections indeed showed sig-
nificantly attenuated virulence compared with non-
supplemented infections (Fig. 2A–C; Weibull curve
comparison: z¼ 3.10–7.82, P< 0.001 in all cases).
Notably, infections supplemented with medium and
high concentrations of gallium (corresponding to
the intermediate gallium concentration used in the
in vitro assays, see ‘Methodology’ section) were sig-
nificantly less virulent (z¼ 4.96 and 2.39, P< 0.05 in
both cases) than infections with PAO1pvdD, a mu-
tant defective for pyoverdine production that itself
showed attenuated virulence versus PAO1 (z¼ 3.49,
P< 0.001). Gallium alone appeared to have little ef-
fect on hosts, with levels of virulence not signifi-
cantly different from those seen in saline-injected
controls (Fig. 2A: survival curve comparison:
z¼0.93, P¼ 0.35; Fig. 2B: pairwise proportion
tests for survival rates: X21¼ 0.43, P¼ 0.51).
Bacterial growth in vivo was also significantly
reduced by gallium (Fig. 2D and E). Growth integrals
were lower in gallium-supplemented larvae than in
WT-injected larvae (Fig. 2E; Tukey’s 95% CIs for the
difference: 16.21–21.44%, t¼ 17.24, P< 0.001) and,
moreover, lower than in larvae injected with the sid-
erophore-defective mutant, PA01pvdD (Fig. 2E;
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Tukey’s 95% CI¼ 13.58–18.97%, t¼ 14.45,
P< 0.001).
To investigate empirically the general potential
for resistance against gallium, we performed
experimental evolution with serial batch cultures,
comparing P. aeruginosa exposed to gallium ver-
sus several single- and mixed-antibiotic regimes
(Fig. 3A–E). At first, all treatments were strongly re-
fractory to growth, showing 24 h growth integrals no
more than a third those of untreated controls (range:
5.8–32.3%). Over the course of a 12-day experiment
(a therapy duration that matches clinical standards),
however, the growth in all antibiotic treatments
increased significantly (Fig. 3E; H0 slopes¼ 0: Cp1:
t¼ 5.54, Cp2: t¼ 3.86, Gm1: t¼ 5.43, Gm2: t¼ 9.12,
Mix1: t¼ 5.26, Mix2: t¼ 7.02; P< 0.001 in each
case), and by the final timepoint their growth inte-
grals were comparable to those of the untreated con-
trols at the start of the experiment (Fig. 3A–D).
Gallium-treated cultures, meanwhile, like the
untreated control, did not show a significant trend
toward higher growth (Fig. 3E; H0 slopes¼ 0;
t¼0.30, P¼ 0.76; t¼ 1.60, P¼ 0.11 and t¼0.11,
P¼ 0.91 for control, Ga1 and Ga2, respectively).
Per-capita pyoverdine output was generally
steady over the course of experimental evolution
[Supplementary Fig. S3: H0 slopes¼ 0: control:
z¼ 0.56, P¼ 0.58; Ga1: z¼ 0.45, P¼ 0.65; all antibi-
otic treatments pooled (Day 1 excluded): z¼ 0.83,
P¼ 0.41], with that of the 20 mM gallium treatment
consistently around 2-fold higher than either control
or antibiotic-treated cultures (95% CIs for fold-
difference were 1.86–2.13 versus control, and
1.96–2.24 versus pooled antibiotic treatments).
In the endpoint phenotypic assays performed
under standardized test conditions (CAA and
LB media), lines evolved in the Ga1 treatment
showed no significant change in pyoverdine produc-
tion (Fig. 4A) relative to their ancestor (CAA:
t¼ 0.81, P¼ 0.43; LB: t¼ 0.08, P¼ 0.94) or to lines
evolved under control conditions (CAA: t¼0.49,
P¼ 0.63; LB: t¼ 0.95, P¼ 0.36), suggesting that the
Figure 2. Gallium attenuates P. aeruginosa virulence and growth in G. mellonella larvae. (A–C) Virulence across treatments, as
Kaplan–Meier (stepped lines) and Weibull (smoothed lines) survival curves; proportion surviving (with 95% binomial CIs); and
time-to-death (means and 95% CIs). We estimate that inocula with ‘LOW’ (2.5–50 mM), ‘MED’ (500mM) or ‘HIGH’ (2500 mM)
concentrations of Ga(NO3)3 gave in-host concentrations of0.05 to50 mM (see ‘Methodology’ section). (D) Bacterial density
in vivo (GFP signal in host homogenate; means and 95% CIs from 24 larvae) corrected against saline-injected controls and
scaled relative to PAO1 at 13 h. (E) Mean and 95% CIs of bacterial growth integrals derived from bootstrap replicate time series
(24 replicate splines) from (D)
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high pyoverdine output seen during experimental
evolution was predominantly a plastic response to
gallium (see Fig. 1B). In contrast, the production of
pyocyanin did appear to be elevated in the Ga1
endpoint isolates (Fig. 4B) in CAA medium (ver-
sus ancestor: t¼ 3.40, P¼ 0.004; versus control:
t¼ 3.09, P¼ 0.008) but not in LB medium (versus
ancestor: t¼ 1.69, P¼ 0.12; versus control: t¼ 1.56,
P¼ 0.15).
DISCUSSION
The results reported above indicate that gallium in-
hibits P. aeruginosa growth primarily through extra-
cellular interference with its primary siderophore,
pyoverdine (Fig. 1A); that this growth inhibition
occurs in an infection context too (Fig. 2D and E),
along with a significant reduction in virulence
(Fig. 2A–C); and that resistance to gallium treat-
ments does not evolve easily—at least not in com-
parison to two conventional antibiotics we tested
(Fig. 3).
For gallium to be both optimally effective and
evolutionarily robust as an antibacterial agent, an
appropriately calibrated dose will be key. At lower
concentrations, efficacy should initially increase
with dose, but at too high concentrations, gallium
may increasingly transit across the cell membrane
and begin to interfere directly with iron metabolism,
causing general toxicity to bacteria and host cells
alike (Fig. 1A; [36]). Here, fitness costs are imposed
intracellularly at the individual cell level, and not
extracellularly at the level of the collective, which
would take us back to a classic antibiotic scenario,
with more potential ‘routes to resistance’ and
greater potential for steep fitness gradients among
individual cells. At sub-toxic levels, meanwhile,
where gallium acts primarily through siderophore-
quenching, resistance should evolve less readily.
Furthermore, we saw that the costs and benefits of
siderophore investment itself are also non-linear
functions of gallium concentration, owing to the ex-
istence of a regulatory ‘trap’. Specifically, intermedi-
ate concentrations of gallium induced the highest
levels of replacement pyoverdine production in bac-
teria (Fig. 1B), adding further metabolic stress to
increasingly iron-limited cells. Our in vivo results,
which showed that gallium can suppress virulence
to levels beyond those seen in pyoverdine-deficient
strains (Fig. 2A–C), are consistent with the interpret-
ation that an appropriate dose of gallium not only
restricts bacterial iron uptake but can also impose a
costly metabolic burden. Given our understanding
of the regulation of pyoverdine production, this
Figure 3. Evolutionary potential for resistance against gallium treatment. (A–D) Over the course of experimental evolution, daily
growth integrals for cultures treated with various antibiotics rose significantly, while the growth of gallium treated cultures did
not. (E) Slope coefficients for linear fits through data in (A–D), expressed as % of growth of control at Day 1. In all cases, symbols
and error bars show means and 95% CIs of six replicate cultures
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hump-shaped association between pyoverdine in-
vestment and gallium is to be expected. Positive
feedback occurs when incoming Fe3þ-bound sidero-
phores act via the receptor FpvA and the anti-sigma
factor FpvR to activate membrane-bound iron-star-
vation sigma factor PvdS [37]. High cytoplasmic
Fe2þ levels, meanwhile, can generate negative feed-
back. In this case, the Fe2þ induces Fur (ferric uptake
regulator)-mediated repression of pvdS [38]. At low
gallium concentrations, iron uptake into the cell is
steady, so negative feedback keeps pyoverdine
production at some intermediate level, while at
mid-range gallium concentrations, iron uptake be-
comes increasingly restricted, leading to steady
positive feedback, but weaker negative feedback,
and consequently, pyoverdine production increases.
Finally, at high concentrations, iron uptake may be
so severely restricted that the positive feedback loop
fails, and pyoverdine production stalls completely.
Exploiting metabolic ‘traps’ such as this could sig-
nificantly increase the effectiveness of treatments,
but requires that the associated regulatory networks
should be left intact and functional. This raises
another point in favor of extracellular quenching
strategies, as opposed to, say, intracellular-
mediated deactivation of entire molecular pathways.
To what extent should gallium’s antibacterial ac-
tivity be evolutionarily robust? In our selection ex-
periment (Figs 3 and 4A), we saw little evidence of
adaptation to gallium, although perhaps we can still
predict what sort of phenotypic changes could
conceivably confer resistance against gallium-
mediated siderophore quenching, and under which
conditions such adaptions could spread. Below, we
consider several potential evolutionary responses,
which are discussed further in Table 1.
First, let’s consider pyoverdine loss-of-function
mutants, which are known to arise readily under iron
limited conditions [39–41]. In co-infection with sid-
erophore producers, non-producing mutants could
act as cheats—no longer investing in the PG
yet still benefiting from the investment of nearby an-
cestors [5]. Even as opportunities to cheat dwindled,
such mutants could continue to spread, since,
disadvantaged as they would be with respect to
autonomous iron acquisition, they would at the same
time be freed of the substantial extra metabolic bur-
den of pyoverdine production under gallium regimes
(see Fig. 1B). Depending on specific conditions
within host tissues, the net fitness of non-producers
could be not far off that of pyoverdine producers
(Fig. 2E), so the mutants could potentially come to
occupy a substantial share of the population. We saw
no significant change in mean pyoverdine production
in strains evolved under gallium (Fig. 4A), suggesting
that cheats did not gain prominence in these cultures.
However, certain individual lines (three antibiotic
lines and one Ga1 line) went extinct during the course
of the experimental evolution, and this extinction
was in each case accompanied by a crash in per cap-
ita pyoverdine production levels (Supplementary
Fig. S3), which would be consistent with a scenario
Figure 4. Resistance-related phenotypic changes following experimental evolution under gallium treatment. Pyoverdine (A) and pyocyanin (B) production under
standardized test conditions (dark bars¼ LB medium, light bars¼CAA medium) of ancestral PAO1, knock-out strains (i.e. negative controls), control lines
(evolved without gallium) and gallium-selected lines. Pyoverdine measures are scaled to that of PAO1 in CAA, whereas pyocyanin is scaled to that of PAO1 in LB.
Asterisks indicate cases where Ga-selected lines were significantly different from their ancestor and unexposed control lines. Error bars give 95% CIs of
3–6 replicates
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Table 1. How likely is resistance against gallium-mediated pyoverdine quenching?
Mutant phenotype Why resistant? Likelihood for mutant to arise Likelihood for mutant to spread
Pyoverdine production
reduced or shut down.
No true resistance, as virulence
is only partly restored.
However, mutants could avoid
being ‘trapped’ into high
pyoverdine production
(Fig. 1B), which can be a
substantial fitness drain
(Fig. 2E).
High Low
Pyoverdine-negative mutants arise
readily [39, 41].
In mixed cultures, gallium re-
duces total population density
and the effective group size at
which pyoverdine can be
shared, and these effects both
disfavor the mutant [45, 46].
Pyoverdine modified to
bind iron with greater
specificity.
Iron uptake efficiency, and
hence growth, should
improve.
Low
(a) Pyoverdine has already
evolved high iron specificity
[20]. Further improvements
are unlikely.
(b) Ga3þ and Fe3þ remain
fundamentally very similar in
binding behavior.
Low
(a) Pyoverdine molecules are
shared across the local com-
munity [47], so producers of
the novel and the ancestral
pyoverdine types would benefit
similarly.
Regulatory shift from
producing pyoverdine to
producing pyochelin, a
secondary siderophore
normally deployed in less
iron-limited conditions.
Although pyochelin is generally
a less effective siderophore
than pyoverdine, this strategy
could be advantageous under
extreme conditions (e.g. in
the presence of gallium).
High Low
(a) Like pyoverdine, pyochelin is
also a shared trait, so benefits
would go to non-mutants too.
(b) Gallium can quench pyochelin
too, and so it still inhibits iron
uptake [49].
Regulatory mechanisms already
exist to facilitate facultative
switching between siderophore
types in response to changing
iron stress [48]. Mutations
that alter this switch could
probably arise easily.
Own pyoverdine production
reducedþ specialization
to use heterologous
siderophores from other
co-infecting species.
Ceasing pyoverdine production
would reduce personal costs,
and heterologous sidero-
phores could offer
compensatory benefits.
Low Low
(a) Most siderophores (e.g.
desferrioxamine) are still prone
to bind gallium [51].
(b) Wild-type P. aeruginosa can
also facultatively switch to
heterologous siderophore use
whenever such siderophores
become available [50].
Although P. aeruginosa can al-
ready take up heterologous
siderophores (e.g.
enterobactin, desferrioxamine)
[50], this route would require
co-infection with a bacterium
that produces an accessible
siderophore.
Own pyoverdine production
reducedþ specialization
to take up iron directly
from the host.
Ceasing pyoverdine production
would reduce personal costs,
while iron from other sources
could offer compensatory
benefits.
High Low
(a) Some host iron chelators
might also bind gallium (e.g.
citrate).
(b) Wild-type P. aeruginosa can
also facultatively switch to al-
ternative uptake mechanisms
when such sources become
available [50].
P. aeruginosa already possesses
the means to take up iron in
various forms [50], including
when it is in complex with
hosts’ iron chelators. A simple
switch in a regulatory pathway
might be all that is required.
Upregulated production of
reducing agents
(e.g. pyocyanin), which
extracellularly reduce
ferric to ferrous iron.
Reducing agents increase avail-
ability of the more soluble
ferrous form of iron (Fe2þ),
which can be taken up with-
out the need for siderophores.
High Low
(a) Increased production of a me-
tabolite would induce extra
costs.
(b) Like pyoverdine, pyocyanin is
also a shared trait, so benefits
(in the form of ferrous iron)
would go to non-mutants too.
Upregulation of an already
existing trait could be
achieved easily [30].
Here, we consider various mutant phenotypes that could putatively confer resistance, and propose hypotheses regarding the likelihood of emergence
and spread in each case.
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of siderophore-non-producing cheats spreading
in these cultures. In any event, the rise of such
mutants should still lead to less virulent infections
(Fig. 2A–C; [42–44]).
Alternative scenarios for evolutionary responses
to gallium treatment could involve modifying
pyoverdine to have substantially greater affinity
for Fe3þ than for Ga3þ, or switching to ‘backup’ sid-
erophores relatively less susceptible to gallium
(Table 1). Such mutations could conceivably arise
but in each scenario we would expect attendant
selection for the mutation to be relatively weak be-
cause, as PGs, these alternative or modified sidero-
phores’ benefits would still be accessible to all cells
within diffusion range, including those lacking the
novel mutation. In addition, gallium and iron remain
fundamentally similar in their physical properties,
such that gallium will still bind—to some extent at
least—any modified siderophore.
Further possible evolutionary responses could
involve mutants that specialize in the direct uptake
of Fe3þ-containing compounds produced by other
competing microbes (i.e. inter-specific cheats),
or present as chelators in the host tissues. Such mu-
tations are also conceivable, given that bacteria al-
ready possess a diversity of iron-uptake machineries
[50]. However, considering that gallium can displace
Fe3þ from other compounds too, it is not clear that
such strategies would offer any clear advantages
over siderophore-mediated uptake.
Finally, bacteria could potentially sidestep their
dependence on the Fe3þ form of iron (prevalent
under oxygen replete and neutral pH conditions)
by altering their environment to increase the extra-
cellular availability of the more bio-available Fe2þ
ions. Indeed, overproducers of pyocyanin, a redox-
active metabolite, have recently been reported to be
refractory to gallium [30], and in our own experi-
ments, we did see a weak but significant mean
increase in pyocyanin production under certain
conditions among cultures evolved under gallium
treatment (Fig. 4B). However, such metabolites
are themselves PGs, so the spread of over-producers
could be constrained in due course by the free-
loading behavior of variants that produce less, yet
still benefit by the increased availability of Fe2þ ions.
In our experimental infections, we observed that
gallium supplementation reduced both the virulence
and the in-host fitness of P. aeruginosa (Fig. 2).
However, pathogen fitness and virulence will not
always be strongly positively correlated [43, 52].
For example, we showed that intermediate gallium
induced overexpression of pyoverdine (Fig. 1B), and
in some contexts, this could potentially lead to
higher virulence, given that pyoverdine production
is linked to certain other virulence factors [53, 54].
Indeed, while gallium is generally known to reduce
virulence [19], one recent study [55] showed that in
very dense cultures, gallium supplementation actu-
ally upregulated production of certain virulence fac-
tors. Thus, while gallium represents a promising way
to reduce bacterial load, its overall effectiveness in
reducing damage to a host will, as always, depend
also on the particular characteristics of the host and
its interaction with the pathogen.
CONCLUSIONS AND IMPLICATIONS
Gallium has seen application in medical contexts for
years (e.g. as an anti-cancer drug [56]) and has pre-
viously been proposed, and tested, as a treatment
against bacterial infections [19, 25, 57, 58]. Gallium
can be directly toxic at high concentrations, but here,
working with concentrations below this toxic
range, we have focused on its capacity to indir-
ectly affect bacteria through disruption of sidero-
phore-mediated iron uptake. Specifically, gallium
quenches siderophores extracellularly, starving cells
of iron and pushing them into a metabolically costly
regulatory trap from which there seems to be little
scope for evolutionary escape. In light of our results,
we contend that this approach—and more generally
the extracellular targeting of PGs—could curb mi-
crobial virulence in an evolutionarily robust manner,
and therefore represents a promising alternative to
our dwindling succession of traditional antibiotics
[59–61].
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Figure S1. 
 
Figure S1. Reliability of proxy measures for pyoverdine. (A) Differentially diluted 24-hr LB 
cultures of PA01ΔpvdD-gfp, a strain constitutively expressing GFP yet defective for pyoverdine 
production, still show some signal in the pyoverdine fluorescence channel (400|460 nm) that 
correlates significantly with their level of GFP fluorescence (488|520 nm; open symbols). (B) 
Conversely, purified and resuspended pyoverdine, diluted to different concentrations in 0.8% saline, 
similarly showed some signal leakage into the GFP channel (open symbols). In both cases, 
however, the magnitude of signal leakage was minor compared to magnitude of signal recorded 
under the conditions of our primary experiments. To illustrate this, we have overlaid on both panels 
the same subset of data from Fig. 1, where PAO1pvdA-gfp was grown under iron-limited conditions 
without added gallium, and assayed for both measures (filled symbols). (C) A 200 µM dose of 
purified pyoverdine in our standard iron-limited CAA medium, when supplemented with 50 µM or 
more of gallium, showed a nearly 2-fold higher signal in the 400|460 nm pyoverdine fluorescence 
channel. Alterations of the fluorescent properties of pyoverdine when bound to iron, unbound, or 
bound to gallium have previously been described, and where appropriate we applied correction 
factors derived from the fitted curves shown here to account for this potential bias in our data.  
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Figure S2. 
 
Figure S2. Reliability of GFP-signal as a proxy for growth of bacteria constitutively expressing 
GFP. (A) GFP-signal produced by PAO1-gfp correlates significantly with cell density in vitro 
(measured as optical density at 600 nm of cultures after 24hr growth in iron-limited CAA medium; 
filled symbols and solid line) and in vivo (homogenate recovered from Galleria mellonella larvae 
experimentally infected with PAO1-gfp as described in main text, and here pooled across all blocks 
and time-points sampled; open symbols and dotted line). Summary statistics for simple linear 
regressions are provided in each case. (B) As expected, GFP-signal does not significantly increase 
over time in saline-injected larvae and, at the final timepoint, remains 5.85 ± 0.72 SE fold lower 
than the signal from larvae injected with the poorest performing of bacterial strains (i.e. 
PAO1pvdD-gfp), suggesting that auto-fluorescence from larval tissues was negligible.
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Figure S3. 
 
Figure S3. Pyoverdine production during experimental evolution of P. aeruginosa under gallium or 
antibiotic treatments. Per-capita pyoverdine production (400|460nm / OD at 600 nm) was 
consistently ~2 fold higher in 20 µM gallium-treated cultures than in other treatments. Thin lines 
depict three individual replicates in which growth crashed, attended by concomitant declines in 
pyoverdine production. Symbols and error bars show means and 95% CIs of 6 replicate cultures.  
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Abstract
Given the rise of bacterial resistance against antibiotics, we urgently need alternative 
strategies to fight infections. Some propose we should disarm rather than kill bacteria, 
through targeted disruption of their virulence factors. It is assumed that this approach 
(i) induces weak selection for resistance because it should only minimally impact bac-
terial fitness, and (ii) is specific, only interfering with the virulence factor in question. 
Given that pathogenicity emerges from complex interactions between pathogens, 
hosts and their environment, such assumptions may be unrealistic. To address this 
issue in a test case, we conducted experiments with the opportunistic human patho-
gen Pseudomonas aeruginosa, where we manipulated the availability of a virulence fac-
tor, the iron- scavenging pyoverdine, within the insect host Galleria mellonella. We 
observed that pyoverdine availability was not stringently predictive of virulence and 
affected bacterial fitness in nonlinear ways. We show that this complexity could partly 
arise because pyoverdine availability affects host responses and alters the expression 
of regulatorily linked virulence factors. Our results reveal that virulence factor ma-
nipulation feeds back on pathogen and host behaviour, which in turn affects virulence. 
Our findings highlight that realizing effective and evolutionarily robust antivirulence 
therapies will ultimately require deeper engagement with the intrinsic complexity of 
host–pathogen systems.
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O R I G I N A L  A R T I C L E
Manipulating virulence factor availability can have complex 
consequences for infections
Michael Weigert1,2 | Adin Ross-Gillespie1,3 | Anne Leinweber1 | Gabriella Pessi1 |  
Sam P. Brown4 | Rolf Kümmerli1
1  | INTRODUCTION
The pervasive idea that virulence—the damage a host experiences 
during infection—follows more or less directly from pathogen load 
has shaped our view of infectious disease since the early days of germ 
theory (Anderson & May, 1979; Bastian, 1875; Evans, 1976; Frank, 
1996; Pasteur, 1880; Stearns & Koella, 2008) and has underpinned 
our clinical quest to eradicate harmful microbes (Allison, Brynildsen, 
& Collins, 2011; Dagan, Klugman, Craig, & Baquero, 2001; Russell, 
2011). However, advances over the years have revealed that the 
severity of an infectious disease depends on much more than just 
the sheer number of pathogens present; rather, it derives from com-
plex interactions between the pathogen, its host and the prevailing 
abiotic and biotic ecological conditions (Bull & Lauring, 2014; de 
Lorenzo, 2015; Méthot & Alizon, 2014; Schmid- Hempel, 2011). In 
other words, a microbe’s pathogenicity is not so much about what 
it is and how abundant it is, but what it does, when it does it and to 
whom.
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These insights have important consequences for antibacterial 
therapies that seek to control rather than eradicate infections (Vale 
et al., 2016). In particular, “antivirulence” approaches have been seen 
as promising alternatives to classic antibiotics (Allen, Popat, Diggle, & 
Brown, 2014; Cegelski, Marshall, Eldridge, & Hultgren, 2008; Rasko 
& Sperandio, 2010; Vale et al., 2016). Such therapies seek to disarm 
rather than kill pathogens and do so by inhibiting the synthesis or 
the functioning of virulence factors (e.g. toxins, tissue- degrading en-
zymes, iron- scavenging siderophores, quorum sensing signals; Rahme 
et al., 1995; Miethke & Marahiel, 2007; Nadal Jimenez et al., 2012; 
LaSarre & Federle, 2013). The appeal of this strategy is that any ef-
fects on bacterial fitness should be relatively minor, and therefore, 
such treatments should induce only relatively weak selection for re-
sistance (André & Godelle, 2005; Pepper, 2012). However, given the 
above- mentioned complexities intrinsic in infectious diseases, we 
can expect that in many cases, a given antivirulence drug will have 
effects that extend beyond simply quenching the targeted virulence 
factor. We might have all sorts of unanticipated secondary effects on 
the behaviour of the pathogen and its host. For example, the suppres-
sion of one virulence factor could pleiotropically affect the regulation 
of another virulence factor due to regulatory linkage at the genetic 
level (Balasubramanian, Schneper, Kumari, & Mathee, 2013; García- 
Contreras et al., 2014; Herrera, García- Arriaza, Pariente, Escarmís, & 
Domingo, 2007; Nadal Jimenez et al., 2012). Furthermore, virulence 
factors often serve as cues for hosts to mount an immune response 
(Miyashita, Takahashi, Ishii, Sekimizu, & Kaito, 2015; Park et al., 2014; 
Schmid- Hempel, 2005; Taszlow & Wojda, 2015), so interfering with 
some virulence factors’ availability could indirectly modulate host 
responses.
In the light of this inherent complexity, it seems challenging to 
predict how a specific antivirulence therapy will likely affect bacterial 
load and treatment efficacy. If indeed the treatment causes second-
ary effects of the sort envisaged above, we might need to carefully 
re- evaluate previous claims on the evolutionary robustness of such 
therapies. Complex interactions between pathogen and host fac-
tors could bring into play a multitude of different traits, all of which 
would be potential targets upon which natural selection could act on. 
Consequently, there could still be considerable selection for pathogen 
variants that are resistant to the treatment and/or become more viru-
lent (Vale, Fenton, & Brown, 2014; Vale et al., 2016).
Here, we use the opportunistic human pathogen Pseudomonas 
aeruginosa as a test case to investigate the consequences of manip-
ulating virulence factor availability. This bacterium relies on a number 
of virulence factors to establish infections in animals and humans, in-
cluding immune- compromised cystic fibrosis patients (Lyczak, Cannon, 
& Pier, 2002; Papaioannou, Utari, & Quax, 2013; Rahme et al., 2000). 
One particularly well- studied virulence factor is pyoverdine, a sid-
erophore secreted into the local environment to scavenge iron from 
host tissue (Cornelis & Dingemans, 2013; Harrison, Browning, Vos, 
& Buckling, 2006; Meyer, Neely, Stintzi, Georges, & Holder, 1996). 
Pyoverdine is a multifunctional molecule. It can be shared as public 
good between cells for iron uptake to stimulate growth and biofilm 
formation (Banin et al., 2008; Buckling et al., 2007). It is also used as a 
signalling molecule to control its own expression, and the synthesis of 
two additional virulence factors, exotoxin A and protease IV (Lamont, 
Beare, Ochsner, Vasil, & Vasil, 2002). Additionally, it can act as a 
toxin by interfering with mitochondrial iron homoeostasis (Kirienko, 
Ausubel, & Ruvkun, 2015). For all those reasons, pyoverdine has 
been identified as a suitable target for antivirulence therapies (Banin 
et al., 2008; Bonchi, Frangipani, Imperi, & Visca, 2015; Bonchi, Imperi, 
Minandri, Visca, & Frangipani, 2014; Kaneko, Thoendel, Olakanmi, 
Britigan, & Singh, 2007; Lamont et al., 2002; Ross- Gillespie, Weigert, 
Brown, & Kümmerli, 2014; Visca, Imperi, & Lamont, 2007). In this 
study, we manipulated the availability of pyoverdine in the context of 
experimental infections of greater waxmoth larvae (Galleria mellonella). 
We investigated how interference with this virulence factor affects (i) 
bacterial growth within the host; (ii) the host’s response to infections; 
(iii) the pleiotropic regulatory links to other virulence factors; and (iv) 
how these factors combine and determine the overall level of viru-
lence the host experiences. Building from previous work, we reduced 
the in vivo availability of pyoverdine by supplementing bacterial inoc-
ula with gallium, an iron mimic that inactivates pyoverdine molecules 
by binding irreversibly to them in place of iron (Kaneko et al., 2007; 
Ross- Gillespie et al., 2014). In addition, we also explored pathogen and 
host responses under conditions of increased pyoverdine availabilities. 
This allows us to test more generally how predictive virulence factor 
availability is for disease severity.
2  | MATERIALS AND METHODS
2.1 | Strains and media
Our experiments featured the clinical isolate P. aeruginosa PAO1 
(ATCC 15692), a pyoverdine- defective knockout strain derived from 
this wild type (PAO1ΔpvdD), and three derivatives of these strains 
engineered via chromosomal insertion (attTn7::ptac- gfp, attTn7::ptac- 
mcherry) to constitutively express fluorescent proteins—that is PAO1- 
gfp, PAO1- mcherry and PAO1ΔpvdD- gfp. Overnight cultures were 
grown in 8 ml Luria–Bertani (LB) medium in 50- ml Falcon tubes and 
incubated at 37°C, 200 rpm for 16–18 hr. For all experiments, we sub-
sequently diluted the overnight cultures in 0.8% NaCl saline solution. 
For in vitro assays, we used iron- limited CAA medium (per litre: 5 g 
casamino acids, 1.18 g K2HPO4*3H2O, 0.25 g MgSO4*7H2O, 100 μg/ml 
human apotransferrin, 20 mM NaHCO3 and 25 mM HEPES buffer). 
Human apotransferrin in combination with NaHCO3 (as cofactor) is 
a strong iron chelator, which prevents non- siderophore- mediated 
iron uptake. All chemicals were purchased from Sigma- Aldrich, 
Switzerland. Pyoverdine was isolated using the protocol by Meyer 
et al. (1997).
2.2 | Manipulation of pyoverdine availability
In both our in vitro and in vivo assays, we reduced and increased pyo-
verdine availability by supplementing bacterial inocula with, respec-
tively, either gallium nitrate or purified pyoverdine. Gallium is an iron 
mimic that inactivates pyoverdine molecules by binding irreversibly 
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to them in place of iron. It thereby lowers pyoverdine availability in 
a dose- dependent manner (Kaneko et al., 2007; Ross- Gillespie et al., 
2014). The addition of pyoverdine immediately increases availability 
after inoculation, which has been shown to stimulate bacterial growth 
in vitro (Kümmerli & Brown, 2010). For in vitro experiments, we varied 
gallium and pyoverdine concentrations from 5 to 250 μM. For in vivo 
experiments, we prepared inocula with 10- fold higher concentrations, 
as we assumed that upon injection into a host larva’s haemolymph (a 
total volume of approximately 100 μl; Harding, Schroeder, Collins, & 
Frankel, 2013), our infection inoculum (a 10 μl volume) would become 
diluted by a factor of approximately ten. Hereafter we report in vivo 
concentrations as estimated final concentrations, adjusted to reflect 
this assumed 10- fold dilution.
2.3 | In vitro growth and pyoverdine assays
To assess how our treatment regimes affect pyoverdine availability 
and bacterial growth, we performed in vitro growth assays. Overnight 
LB cultures (PAO1 and PAO1ΔpvdD) were washed twice and stand-
ardized for optical density (OD = 2) and then inoculated at 10−3 di-
lution to iron- limited CAA supplemented with either gallium nitrate 
(Ga(NO3)3; 5, 10, 20, 50 and 250 μM) or purified pyoverdine (same 
concentrations), to respectively reduce or enhance the availability of 
pyoverdine. All conditions were carried out in fourfold replication. 
Growth was tracked over 24 hr (37°C) in 200 μl cultures in 96- well 
plates (BD Falcon, Switzerland) using a Tecan Infinite M- 200 plate 
reader (Tecan Group Ltd, Switzerland). We measured OD at 600 nm 
and pyoverdine- associated fluorescence (400 ex | 460 em), every 
15 min following brief shaking of the plate (30s, 3.5 mm orbital dis-
placement). As gallium increases pyoverdine fluorescence, we cor-
rected fluorescence values using a previously published calibration 
curve (Ross- Gillespie et al., 2014).
2.4 | In vivo growth assays
Infections were performed following protocols described in Ross- 
Gillespie et al. (2014). Briefly, final- instar Galleria mellonella larvae, 
standardized for mass and general condition, were surface- sterilized 
with 70% ethanol, inoculated between the posterior prolegs (Hamilton 
syringe; 26s gauge sterile needle) and then individually (randomly) dis-
tributed to the wells of 24- well plate for incubation at 37°C. In vivo 
bacterial growth was assayed as per Ross- Gillespie et al. (2014), using 
GFP fluorescence signal as a proxy for growth. For this reason, we 
infected larvae with bacterial strains harbouring a constitutively ex-
pressed gfp marker (i.e. PAO1- gfp or PAO1ΔpvdD- gfp). Inocula (10 μl) 
contained ~25 colony- forming units (CFU) of either PAO1- gfp sup-
plemented with gallium (50 μM or 250 μM) or pyoverdine (50 μM or 
250 μM), no pyoverdine or the pyoverdine- defective PAO1ΔpvdD- gfp 
as a control treatment. A growth- negative control included the injec-
tion of saline solution. At 17 hr postinfection, larvae (24 per treatment) 
were processed to estimate their bacterial load. Approximately 50% 
of the larvae that had been infected with the wild- type strain were al-
ready dead at this time point. Larvae were individually flash- frozen in 
liquid nitrogen and then ground to fine powder using sterile micropes-
tles. Powderized larval homogenates were resuspended in 1 ml sterile 
H2O and centrifuged at 6300 RCF for 2 min. Thereafter, 200 μl of the 
water- soluble liquid phase of each sample was transferred to a 96- 
well plate and assayed for GFP- associated fluorescence using a Tecan 
Infinite M- 200 plate reader. To examine whether the bacterial load at 
17 hr postinfection is representative of within- host growth dynam-
ics, we repeated the experiment for a subset of treatments (untreated 
wild type, wild type with intermediate (50 μM) gallium or pyoverdine 
concentration, pyoverdine- deficient mutant, saline control). At 13, 15, 
17 and 20 hr, we processed randomly selected larvae (24 per treat-
ment) as described above and measured their bacterial load.
2.5 | Ex vivo growth assays
We investigated the potential influence of host effects on bacterial 
dynamics via ex vivo growth assays in haemolymph. In a first step, we 
primed G. mellonella larvae by inoculating them with bacterial wild- 
type cultures featuring manipulated levels of pyoverdine (by supple-
menting inoculum with either intermediate (50 μM) concentrations 
of gallium or pyoverdine). As controls, we primed larvae by infecting 
them with either the pyoverdine- deficient strain, pyoverdine alone, 
heat- killed wild- type bacteria or the saline control. In a second step, 
we then measured bacterial growth in haemolymph extracted from 
these primed larvae. The priming inocula were administered as per 
the infection protocol described above. Inoculated larvae were dis-
tributed, in groups of 4, to petri dishes and incubated at 37°C. After 
14 hr, the petri dishes were placed on ice for 15 min to anaesthetize 
the larvae prior to haemolymph extraction. A small incision was made 
in the posterior segment using a sterile scalpel, and haemolymph was 
drained with the aid of gentle pressure (Harding et al., 2013). From 
each sample, 25 μl of haemolymph was immediately stabilized with 
15 μl of an ice- cold pH 6.5 cacodylate buffer (10 mM Na- C2H7AsO2 
and 5 mM CaCl2) and 15 μl of a saturated propylthiouracil solution to 
inhibit melanization. Samples were then centrifuged (514 RCF, 2 min) 
to separate the liquid haemolymph fraction from any solid tissue con-
taminants, and 30- μl aliquots were transferred to individual wells of a 
96- well plate, each containing 70 μl of saline solution. To kill the prim-
ing strains and any other bacteria that may have been present in the 
haemolymph as part of the natural larval microbiota, we added gen-
tamicin to the haemolymph/buffer mixture to a final concentration of 
20 μg/ml (a concentration known to kill susceptible P. aeruginosa; Choi 
et al., 2005). Subsequently, we inoculated wells with bacteria from an 
overnight culture (adjusted to an OD = 2 and subsequently diluted 
to 10−4) of a gentamicin- resistant PAO1-mcherry strain (this strain 
showed the same growth pattern as the untagged wild- type strain). 
The plate was transferred to a Tecan Infinite M- 200 plate reader for 
24 hr of incubation at 37°C. Every 15 min, we measured cell density 
(measured via the mCherry- associated fluorescence: 582 ex | 620 em; 
note: using optical density as a proxy for cell density is not reliable in 
this naturally turbid medium). These experiments allowed us to ascer-
tain (i) whether bacterial growth in haemolymph is affected by a host’s 
history of prior infection and (ii) whether the availability of pyoverdine 
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during priming predicts subsequent bacterial growth. Note that re-
sidual pyoverdine from the priming inocula was below detection limit 
after haemolymph extraction, and therefore should not influence later 
bacterial growth patterns.
2.6 | Molecular investigation of pyoverdine- 
mediated pleiotropy
Because pyoverdine is not only a virulence factor but also a signal-
ling molecule, manipulating pyoverdine availability might also affect, 
via interaction with the PvdS iron- starvation sigma factor, the pro-
duction of two additional virulence factors, exotoxin A and protease 
IV (Lamont et al., 2002; Ochsner, Johnson, Lamont, Cunliffe, & Vasil, 
1996; Wilderman et al., 2001). We used qPCR to explore whether 
our extrinsic manipulation of pyoverdine levels could change 
pyoverdine- mediated signalling and therefore pleiotropically affect 
expression of genes for virulence factor production (pvdS, toxA cod-
ing for exotoxin A, prpL (alternative name: piv) coding for protease IV 
and pvdA coding for one of the pyoverdine synthesis enzymes). PAO1 
cells were grown until early- and mid- exponential growth phases in 
20 ml standard CAA (in a sterile 500- ml Erlenmeyer) containing ei-
ther (i) no supplement, (ii) 10 μM Ga(NO3)3 (to reduce pyoverdine 
availability), (iii) 200 μM purified pyoverdine (to increase pyoverdine 
availability) or (iv) 100 μM FeSO4 (our negative control under which 
pyoverdine production should be completely switched off; Kümmerli, 
Jiricny, Clarke, West, & Griffin, 2009). RNA was extracted using a 
modified hot acid phenol protocol and purified as in Pessi et al. (2007, 
2013). Residual DNA in the sample was eliminated using RQ1 RNase- 
free DNase I, and purification was performed using the RNeasy Mini 
Kit (Qiagen). Absence of DNA was verified by PCR using the prim-
ers specified in Table S1, and 40 cycles with the GoTaq Polymerase 
(Promega, Switzerland). RNA quality in the purified samples was 
then assessed using RNA Nano Chips (Agilent 2100 Bioanalyzer; 
RIN (RNA integrity number) >7.6). First- strand cDNA synthesis with 
10 μg of total RNA from each sample was performed with M- MLV 
reverse transcriptase RNase H Minus (Promega) and random prim-
ers (Promega). cDNA was subsequently purified with the MinElute 
PCR Purification Kit (Qiagen). The expression of Pseudomonas aer-
uginosa PAO1 genes PA2399 (pvdD), PA2426 (pvdS), PA1148 (toxA) 
and PA4175 (prpL) was analysed with a Stratagene MX300P instru-
ment (Agilent) using GoTaq qPCR Master Mix (Promega). All PCRs 
were analysed in triplicate with three cDNA dilutions (15, 7.5 and 
3.25 ng) and 0.4 μM of individual primers in a total volume of 25 μl 
per reaction. Primers (Table S1) were designed using Primer3Plus 
(Untergasser et al., 2007) and subsequently verified by PCR. Fold 
changes were calculated using the ΔΔCT method (Pfaffl, 2001) using 
the primary sigma factor rpoD (PA0576) as housekeeping gene for 
data normalization.
2.7 | Virulence assays
Infections were performed as described above. Inocula (10 μl) 
contained ~25 CFU of P. aeruginosa from an overnight culture, 
resuspended in saline solution and supplemented with either gallium 
nitrate (5 μM, 50 μM, 250 μM), pyoverdine (10 μM, 50 μM, 250 μM) 
or neither. Controls included saline- only, gallium- only (50 μM and 
250 μM) and pyoverdine- only inocula (50 μM and 250 μM), and also 
the PAO1ΔpvdD strain, defective for pyoverdine production. The 
vitality of all larvae (i.e. spontaneous movement/response to tactile 
stimulation) was assessed hourly, starting at 10 hr postinjection. Some 
of the larvae (n = 25, 3.14%) either started pupating while under ob-
servation or died prematurely during the first 10 hr postinjection—
presumably as a result of handling—and hence were excluded from 
further analyses.
2.8 | Statistical analysis
We used the functions from the “grofit” R package to fit spline curves 
to the growth and pyoverdine production trajectories. From these 
fitted curves, we extracted growth parameters. In particular, we fo-
cused on growth integrals (areas under curves), which combine infor-
mation from the lag phase, growth rate and yield. Growth integrals 
are particularly useful for nonlogistic growth trajectories as observed 
throughout our experiments.
Survival curves were analysed by fitting parametric Weibull sur-
vival curves with the aid of functions from the “survival” R package 
(Therneau & Grambsch, 2000). From the fitted models, we extracted 
the hazard ratios and used those values to estimate the mortality risk 
of larvae within each treatment. To confirm the robustness of our anal-
ysis, we also performed Cox proportional hazards regression, which 
yielded qualitatively similar results.
We used both parametric and nonparametric statistical models to 
test for treatment effects. Specifically, we used Kendall rank correla-
tion analyses to test for associations between pyoverdine availability, 
growth, host response and virulence. The data from our in vivo and 
ex vivo growth experiments did not meet the criteria of normally dis-
tributed residuals and the homogeneity of variances, which precluded 
the use of parametric statistical tests. For these analyses, we used the 
nonparametric Kruskal–Wallis test. All analyses were performed in R 
3.3.0 (R Development Core Team 2015).
3  | RESULTS
3.1 | Treatment effects on in vitro bacterial 
pyoverdine availability and growth
We first tested whether our treatment regime (i.e. adding gallium to 
quench pyoverdine or supplementing additional pyoverdine) indeed 
altered pyoverdine availability as intended. We found that our treat-
ment regime had a positive linear effect on pyoverdine availability 
(Figure 1a; Kendall’s correlation coefficient: τ = .75, p < .001, meas-
ured during the first 8 hr of the growth period when pyoverdine is 
most needed to overcome iron limitation; Kümmerli & Brown, 2010). 
Moreover, we found that our manipulation of pyoverdine avail-
ability had a significant linear effect on bacterial growth (Figure 1b; 
τ = .93, p < .001): adding gallium reduced growth, while pyoverdine 
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supplementation accelerated growth relative to the unsupplemented 
wild type. Taken together, our in vitro experiments show that our 
treatment scheme successfully manipulates pyoverdine availability 
and that pyoverdine is a growth promoter, essential for bacteria to 
thrive in iron- limited medium.
3.2 | Nonlinear effects of pyoverdine availability on 
in vivo bacterial growth
Pyoverdine availability also had significant effects on bacterial growth 
within the G. mellonella larvae (Kruskal–Wallis test for differences 
between treatments: χ2 = 34.80, p < .001; Figure 2), but the over-
all effect was not linear. Instead, bacterial load peaked in infections 
with the unsupplemented wild type (i.e. at intermediate pyoverdine 
availability). Both the addition of gallium and pyoverdine significantly 
reduced bacterial growth compared to unsupplemented wild- type in-
fections (for gallium 50 and 250 μM combined: χ2 = 8.68, p = .013; 
for pyoverdine 50 and 250 μM combined: χ2 = 6.66, p < .010). 
Bacterial growth also significantly peaked in infections with the un-
supplemented wild type when considering the entire growth trajec-
tories and not only a single time point (Fig. S1), thereby confirming 
the above pattern.
One possible explanation for the absence of a linear relationship 
between pyoverdine availability and in vivo growth is that pyoverdine 
might not be required for bacteria to thrive within the host. However, 
two control experiments speak against this hypothesis. First, the 
growth of a pyoverdine- deficient knockout strains was significantly 
impaired in host infections compared to the wild type (Kruskal–Wallis 
test: χ2 = 7.54, p < .001; Figure 2). Second, ex vivo growth of wild- 
type bacteria in extracted haemolymph demonstrated significant iron 
limitation and high pyoverdine production in this medium (Fig. S2). 
Altogether, these results indicate that pyoverdine is important for iron 
scavenging and growth within the larvae.
3.3 | Pyoverdine availability affects host responses
To investigate whether bacteria and/or pyoverdine availability triggers 
variation in host responses, we tracked growth of a wild- type strain 
ex vivo in haemolymph extracts from larvae previously primed under 
different conditions. Ex vivo bacterial growth in haemolymph indeed 
significantly differed depending on the infection history of the lar-
vae (Figure 3; Kruskal–Wallis test: χ2 = 10.59, p = .014, including the 
pyoverdine manipulation regimes and the saline control). Specifically, 
bacteria showed significantly lower growth in haemolymph from 
wild- type- primed larvae than in haemolymph from saline- primed lar-
vae (χ2 = 4.11, p = .043). Furthermore, we found a significant negative 
association between the availability of pyoverdine in the priming in-
ocula and the subsequent ex vivo bacterial growth (Figure 3; Kendall’s 
τ = −.21, p = .023). Control experiments revealed that a significant 
host response can be triggered by multiple stimuli: priming larvae 
F IGURE  1 Our treatment regime significantly affected pyoverdine availability (a) and bacterial growth (b) in linear ways. To capture the 
dynamics of pyoverdine availability (first 8 hr) and growth (24 hr) in bacterial cultures, we used integrals (i.e. area under the curve) for analysis. 
Nonlinear patterns in (a), for example for the 10 μM and 20 μM pyoverdine supplementations, can arise because bacteria plastically adjust their 
pyoverdine production level according to their need (Kümmerli et al., 2009), such that de novo production and supplementation can balance 
each other out over time. Symbols and error bars represent mean estimates and 95% confidence intervals, respectively, across four independent 
replicates
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with non- pyoverdine- producing bacteria, pyoverdine alone or heat- 
killed bacteria all resulted in a similarly increased response relative 
to the saline priming (Kruskal–Wallis test comparing pooled control 
treatments versus the saline treatment: χ2 = 8.24, p = .004). Overall, 
our findings suggest that haemolymph primed with bacteria has a 
growth- inhibiting effect on P. aeruginosa and that this effect can vary 
plastically over time in response to pyoverdine availability.
3.4 | Pyoverdine availability affects the expression of 
other virulence factors
In addition to its function as a siderophore, pyoverdine is also a 
signalling molecule, which controls its own production and the 
synthesis of two other virulence factors, namely protease IV and 
exotoxin A (Beare, For, Martin, & Lamont, 2002; Lamont et al., 2002) 
(Figure 4). It is therefore well conceivable that the experimental ma-
nipulation of pyoverdine availability also affects the expression of 
these other virulence factors. To test this hypothesis, we performed 
in vitro qPCR experiments, following the expression of the genes 
pvdS, pvdA, prpL and toxA across three levels of pyoverdine avail-
abilities and two time points (early- and mid- exponential phase). We 
examined these time points because pleiotropy relatively early in 
the growth cycle is likely to have the biggest effect on subsequent 
pathogen growth and virulence. The four genes code for the sigma 
factor PvdS (the main regulator of all three virulence factors), PvdA 
(enzyme involved in pyoverdine synthesis), protease IV and exotoxin 
A (Figure 4). Taking the unsupplemented wild- type bacteria growing 
in our standard iron- limited medium as a reference, we found that 
the addition of iron dramatically downregulated the expression of 
all four genes (Table 1). This suggests that all three virulence factors 
(pyoverdine, protease IV and exotoxin A) are significantly expressed 
under the imposed iron- limited conditions (see also Ochsner, 
Wilderman, Vasil, & Vasil, 2002). Next, we examined whether gene 
expression levels change as a function of pyoverdine availability. 
We found that pyoverdine manipulation either did not affect gene 
expression or resulted in the downregulation of interlinked genes 
(Table 1). As there were no marked differences in gene expression 
profiles between the early- and the mid- exponential growth phase, 
F IGURE  2 Pyoverdine availability has nonlinear effects on 
P. aeruginosa growth in G. mellonella larvae. Bacterial load (measured 
17 hr postinfection) peaked in infections with the unsupplemented 
wild type, while the supplementation of both gallium (blue) and 
pyoverdine (red) resulted in a significant drop of bacterial load. 
Infections with a pyoverdine- deficient strain also resulted in a 
significant growth reduction compared to wild- type infections, 
indicating that pyoverdine is important for growth in this host. 
Symbols and error bars represent mean estimates and 95% 
confidence intervals, respectively. Numbers on top show sample size 
for each treatment
F IGURE  3 Growth of P. aeruginosa in haemolymph extracted 
from primed larvae demonstrates context- dependent host effects. 
Fourteen hours prior to haemolymph extraction, larvae were primed 
with wild- type bacteria, either alone or supplemented with gallium or 
pyoverdine. Control larvae were primed with saline alone, pyoverdine 
alone, heat- killed wild- type bacteria or a pyoverdine- deficient strain. 
Haemolymph extracts were gentamicin- treated to kill previously 
inoculated bacteria, and growth assays were then performed with a 
gentamicin- resistant wild- type strain. Compared to the saline control, 
haemolymph primed with wild- type bacteria was significantly more 
refractory to subsequent bacterial growth, demonstrating a host 
response to infection. Moreover, we found a significant negative 
correlation between pyoverdine availability during the priming phase 
and the subsequent bacterial growth, indicating that pyoverdine 
is involved in triggering host responses. Symbols and error bars 
represent mean estimates and 95% confidence intervals, respectively. 
Numbers on top show sample size for each treatment
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we pooled the data to identify the genes that were significantly 
downregulated (Figure 4). These analyses revealed that the addi-
tion of gallium (10 μM) slightly but significantly reduced the expres-
sion of pvdS (t3
 = −10.55, p = .002) and pvdA (t3
 = −3.87, p = .031). 
The supplementation of pyoverdine (200 μM) significantly reduced 
the expression of pvdA (t3 = −17.95, p < .001) and toxA (t3 = −4.50, 
p = .020). Our results are promising from a therapeutic perspective, 
as they suggest that the manipulation of pyoverdine availability does 
not increase the expression of the interlinked virulence factors pro-
tease IV and exotoxin A, but rather has a neutral or even a negative 
effect on their expression.
3.5 | Relationship between pyoverdine 
availability and virulence
Our results presented above (Figures 2–4) show that the manipula-
tion of pyoverdine availability has nonlinear effects on bacterial load, 
triggers differential host responses and has slight pleiotropic effects 
on the expression of other virulence factors. How do these factors 
now all combine within the host and determine the overall level of 
virulence associated with pyoverdine manipulation? Overall, our ex-
perimental infections of G. mellonella larvae revealed a significant 
positive association between pyoverdine availability and virulence 
F IGURE  4 Manipulating pyoverdine availability has moderate effects on the pyoverdine signalling network, and generally leads to the 
downregulation of interlinked genes. Pyoverdine production is controlled by the alternative sigma factor PvdS that is itself negatively regulated 
by the ferric uptake regulator FUR, in response to intracellular iron levels. Pyoverdine modulates PvdS activity through a signalling cascade. 
Incoming iron- bound pyoverdine binds to its cognate receptor, thereby triggering the lysis of the membrane- bound antisigma factor FpvR, which 
binds and inhibits PvdS. In turn, membrane- released PvdS triggers increased transcription of pyoverdine synthesis genes, but also activates 
the expression of prpL (encoding the protease IV virulence factor) and toxR (coding for the ToxR regulator that then stimulates the expression 
of exotoxin A). Reduced pyoverdine availability (gallium supplementation, blue bars) moderately but significantly reduced pvdS and pvdA 
expression. Increasing pyoverdine availability (red bars) moderately but significantly reduced pvdA and toxA expression. Shown are mean values 
and standard errors across four replicates. Asterisks indicate significant gene expression changes relative to the unsupplemented wild type 
(p < .05). † indirect regulation via toxR regulator
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(Figure 5; Kendall’s τ = .71, p = .030). Larvae died earlier in infections 
supplemented with pyoverdine, but survived longer when gallium was 
added instead. However, the trend was not altogether monotonic: 
moderately increased pyoverdine availability (10 μM) significantly de-
creased rather than increased the virulence risk (parametric survival 
regression assuming Weibull distribution: coefficient = 0.082 ± 0.028, 
mean ± SE, z = 2.89, p = .004). Such low- pyoverdine- supplementation 
infections showed virulence levels comparable to those of unsupple-
mented infections involving the pyoverdine- deficient PAO1ΔpvdD 
mutant (coefficient = 0.0055 ± 0.028, z = 1.94, p = .846). The gallium- 
supplemented treatments were not ordered monotonically with 
respect to virulence, in that high (250 μM)- gallium- supplemented 
infections were no less virulent than intermediate (50 μM)- gallium- 
supplemented infections (coefficient = 0.043 ± 0.037, z = 1.18, 
p = .238).
4  | DISCUSSION
Our results show that the manipulation of pyoverdine, an important 
virulence factor of the opportunistic human pathogen P. aeruginosa, 
affects bacterial load in infections of G. mellonella larvae in complex 
ways, triggers differential host responses and influences the expres-
sion of other regulatorily linked virulence factors (Figures 2–4). Our 
findings have important consequences for recently proposed an-
tivirulence therapies, targeting pyoverdine- mediated iron uptake 
(Bonchi et al., 2014, 2015; Imperi et al., 2013; Kaneko et al., 2007; 
Ross- Gillespie et al., 2014), because complex interactions between 
bacterial load, host response and regulatory pleiotropy could result 
in unpredictable treatment outcomes (García- Contreras et al., 2014). 
We examined this possibility for our system and found an overall posi-
tive relationship between pyoverdine availability and virulence, but 
also notable deviations from a monotonic pattern. For instance, the 
supplementation of low levels of pyoverdine significantly decreased 
rather than increased virulence, with this treatment reaching virulence 
levels comparable to infections with the pyoverdine knockout strain 
(Figure 5).
Some of the discovered complex nonlinear associations between 
bacterial load, host response, pleiotropy and virulence warrant closer 
examination. For instance, why does increased pyoverdine availabil-
ity (50 μM and 250 μM supplementation regimes) increase virulence 
despite the fact that these treatments reduce bacterial growth in 
TABLE  1 Expression fold changes for P. aeruginosa genes involved in pyoverdine- mediated signalling
Growth Phase Gene
Supplementation regime
100 μM FeSO4  10 μM Ga(NO3)3 200 μM Pyoverdine
Mean SE Mean SE Mean SE
Early- exponential pvdS 0.0003 0.0002 0.3256 0.0199 0.7237 0.1719
pvdA 0.0001 0.0000 0.3442 0.0353 0.3675 0.0159
toxA 0.0544 0.0098 0.9063 0.0161 0.2154 0.0200
prpL 0.2321 0.0375 0.7072 0.3661 1.1106 0.0821
Mid- exponential pvdS 0.0003 0.0002 0.5167 0.0350 0.8273 0.0628
pvdA 0.0003 0.0002 0.7242 0.1163 0.4059 0.0775
toxA 0.0561 0.0092 1.1514 0.1412 0.6463 0.0519
prpL 0.0214 0.0046 0.3776 0.0896 0.3240 0.0143
Expression fold changes of pvdS (encoding the iron- starvation sigma factor PvdS), pvdA (coding for one of the pyoverdine synthesis enzymes), toxA (coding 
for exotoxin A) and prpL (encoding protease IV) are expressed relative to the unsupplemented PAO1 wild- type regime.
F IGURE  5 Relationship between pyoverdine availability and 
virulence, measured as mortality risk of larvae within each treatment. 
Overall, there is a positive correlation between pyoverdine availability 
and virulence with a notable exception. Supplementing the 
infection with 10 μM pyoverdine reduced virulence comparable to a 
pyoverdine- deficient mutant. Symbols and error bars represent mean 
estimates and 95% confidence intervals, respectively. Numbers on 
top show sample size for each treatment
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vivo (Figure 2) and results, in vitro at least, in the downregulation 
of the coupled virulence factor exotoxin A (Figure 4)? One possible 
explanation is that high pyoverdine supplementation triggers an ex-
cessive host response, which is not only curbing bacterial growth, 
but is also damaging the host itself. For instance, G. mellonella pro-
duces the iron chelator transferrin as part of its innate immune 
response (Han, Nam, Seo, & Yun, 2004), a protein which actively 
counteracts the iron- scavenging activities of pathogens (Miethke & 
Marahiel, 2007). Such a host response typically entails costs in terms 
of metabolic burden and autoimmune damage, and therefore must 
be appropriately calibrated (Day, Graham, & Read, 2007; Medzhitov, 
Schneider, & Soares, 2012). An overreaction from the host, perhaps 
in response to a high concentration of pyoverdine, could actually 
exacerbate, rather than reduce, virulence. Important to note is that 
although pyoverdine seems to induce a host response (Figure 3), it is 
not toxic itself, as larvae infected with pyoverdine alone all remained 
healthy (Figure 5).
Another complex association was that when increasing pyoverdine 
availability a little bit (10 μM) compared to the wild- type treatment, 
we observed a significant reduction of virulence (Figure 5). This drop 
can potentially be explained by a host response too, but this time by a 
well- calibrated one, which primarily harms the pathogen while being 
beneficial for the host. If this explanation holds true, then the sup-
plementation of moderate amounts of pyoverdine could represent a 
treatment that boosts host tolerance. Interestingly, treatments that 
increase host tolerance have, in addition to antivirulence approaches, 
been proposed as alternative ways to combat infections (Ayres & 
Schneider, 2012; Medzhitov et al., 2012; Vale et al., 2014, 2016).
Finally, we observed that infections with intermediate amounts 
of gallium (50 μM) were significantly less virulent than infections with 
the pyoverdine- deficient knockout strain (Figure 5). This suggests that 
this treatment has other effects, in addition to simply depriving sidero-
phores from pathogens. One explanation would be that gallium has 
some general toxicity towards bacteria beyond its role in inhibiting 
iron uptake (Bonchi et al., 2014). An alternative explanation, which 
is supported by our previous findings (Ross- Gillespie et al., 2014) but 
also the qPCR data (Figure 4), is that intermediate gallium levels main-
tain pyoverdine synthesis, while high gallium levels completely stall 
the production. This steady production likely imposes a twofold cost 
on bacteria: gallium does not only prevent pyoverdine- mediated iron 
uptake, but also induces continuous replacement of pyoverdine, which 
likely demands a high metabolic investment for very little reward (be-
cause pyoverdine is quenched by gallium once secreted). Given the 
ubiquity of linkages and feedback loops in the genetic architecture of 
bacteria (Dumas, Ross- Gillespie, & Kümmerli, 2013; Fazli et al., 2014; 
García- Contreras et al., 2014; Nadal Jimenez et al., 2012), such fea-
tures are likely important contributors to nonadditive effects between 
pathogen behaviour, fitness and virulence.
Given the complexities of host–pathogen relationships we have 
highlighted in this study, what could be the evolutionary conse-
quences for antivirulence therapies? The central tenet of this ap-
proach was that disarming rather than killing pathogens should induce 
weaker selection for resistance because it exerts only minimal effects 
on pathogen fitness (André & Godelle, 2005; Pepper, 2008; Rasko & 
Sperandio, 2010; Stanton, 2013). Our study demonstrates that an-
tivirulence approaches can in fact substantially modulate pathogen 
fitness (Figure 2; see also Liu et al., 2008), which clearly offers nat-
ural selection the opportunity to favour pathogen variants that are 
partially or fully resistant to the treatment (see Maeda et al., 2012; 
Ross- Gillespie et al., 2014; Allen et al., 2014; for detailed discussion). 
One obvious evolutionary response of pathogens in response to vir-
ulence factor quenching is to overproduce the virulence factor in 
question in order to outpace the quenching activity of the drug. Our 
results indicate that such an adaptation could affect the host in two 
different ways. If the increase in virulence factor production is sub-
stantial, this could lead to the evolution of a more virulent pathogen, 
which causes increased damage to the host in the absence of the 
treatment. Conversely, if the increase in virulence factor production 
is relatively small, then it could positively stimulate host responses, 
which in turn could curb virulence. Evolutionary responses leading to 
increased virulence factor production would likely involve the modifi-
cation of regulatory elements. As evidenced by our study, regulatory 
elements can not only affect the expression of the targeted virulence 
factor, but also modify the expression of additional linked virulence 
factors in the same regulatory network (see Figure 4). How exactly 
such regulatory linkage would alter global virulence factor expression 
profiles of a pathogen in a host and how this feeds back on virulence 
cannot easily be foreseen, and might vary in response to the specific 
host stimuli present in an infection (Park et al., 2014). Finally, there 
might also be variation between host individuals regarding the ex-
tent to which they can cope with altered virulence factor expression. 
Conceivably, for an immunocompromised host even a minor overex-
pression of virulence factors might be fatal, whereas a healthy host 
might be more tolerant and easily able to cope with higher virulence 
factor levels. Taken together, our considerations show that we still 
have very limited understanding of the evolutionary consequences of 
antivirulence therapies. There is definitely a great need for controlled 
experimental evolution studies that measure selection pressures, 
adaptation patterns and host responses at both the proximate and 
ultimate level.
Given our dwindling supply of new antimicrobials, and the increas-
ing prevalence of resistance to those we already have (Fischbach & 
Walsh, 2009; Levy & Marshall, 2004), creative approaches such as an-
tivirulence therapies are certainly required (Perron, Inglis, Pennings, & 
Cobey, 2015; Ross- Gillespie & Kümmerli, 2014). To turn these ideas 
into effective and robust clinical therapies, however, we must delve 
deeper into the complexity of host–pathogen systems.
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Figure S1. Growth trajectories of P. aeruginosa within G. mellonella larvae confirm that gallium and 
pyoverdine supplementation both significantly reduced bacterial growth compared to the 
unsupplemented wildtype (permutation test with 10,000 iterations: p =0.030). In vivo bacterial density 
was estimated from constitutively expressed GFP signal in host homogenates (points). This involved 
destructively sampling up to 96 larvae per treatment (~24 per time point; or n = 6 for the saline 
control). Because we were unable to track infections within an individual through time, we used 
bootstrap resampling of our observed data to generate replicated sets of estimated trajectories, a 
random sample of which are shown (faint lines). Symbols and error bars denote the medians, 2.5% and 
97.5% quantiles from n=10,000 bootstrap-replicated datasets. We fitted splines to each trajectory and 
summarized the overall growth patterns using areas-under-curves. These resulting distributions of 
these growth integrals are given in the final plot (medians with 2.5% and 97.5% quantiles). 
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Figure S2 Growth (A) and pyoverdine production (B) of the wildtype strain and the pyoverdine-
deficient mutant in naive haemolymph extracted from G. mellonella larvae. (A) The supplementation 
of 100 µM FeCl3 to the haemolymph significantly increased the growth of both the wildtype strain and 
the pyoverdine-deficient mutant, demonstrating that iron is a growth-limiting factor in the host 
environment. The observed pyoverdine-production profiles confirmed this assertion (B). Specifically, 
the wildtype strain produced high amounts of pyoverdine in the unsupplemented haemolymph, but 
reduced its investment to baseline level when iron was added to the haemolymph. Numbers on top 
show sample size of each treatment. 
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Gene Sequence (5`→ 3`) 
pvdS (forward) AGG AAG AAG GCC TGA ACG TG 
pvdS (reverse) CCT TGG CGA TGT CCT TCT GT 
pvdA (forward) TGT TCC ACC ACA GCC AGT AC 
pvdA (reverse) GGG TAG CTG TCG TTG AGG TC 
toxA (forward) AAA AGC GCT GGA GCG AAT GG 
toxA (reverse) GGG AAA TGC AGG CGA TGA CTG AT 
prpL (forward) TCT ACA ACA CCA CCC AGT GC 
prpL (reverse) TTG CCC TGC GAG TAC TTC TT 
rpoD (forward) GGG GAT CAA CGT ATT CGA GA 
rpoD (reverse) ATC GAT ATA GCC GCT GAG GA 
 
S1 Table.  Genes and primers used for qPCR. We studied four genes involved in pyoverdine-
mediated signaling, which are pvdS (encoding the iron-starvation sigma factor), pvdA (coding 
for an enzyme critical for pyoverdine synthesis), toxA (coding for exotoxin A), and prpL 
(encoding protease IV). Primers were designed based on sequences from the Pseudomonas 
genome database (www.pseudomonas.com) using the Primer3Plus platform aiming for 200 
bp amplicons.  
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Surface-Attached Bacterial Cells
Abstract
Bacteria secrete a variety of compounds important for nutrient scavenging, com-
petition mediation and infection establishment. While there is a general con-
sensus that secreted compounds can be shared and therefore have social con-
sequences for the bacterial collective, we know little about the physical limits
of such bacterial social interactions. Here, we address this issue by studying
the sharing of iron-scavenging siderophores between surface-attached micro-
colonies of the bacterium Pseudomonas aeruginosa. Using single-cell fluorescent
microscopy, we show that siderophores, secreted by producers, quickly reach
non-producers within a range of 100 µm, and significantly boost their fitness.
Producers in turn respond to variation in sharing efficiency by adjusting their
pyoverdine investment levels. These social effects wane with larger cell-to-
cell distances and on hard surfaces. Thus, our findings reveal the boundaries
of compound sharing, and show that sharing is particularly relevant between
nearby yet physically separated bacteria on soft surfaces, matching realistic nat-
ural conditions.
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Introduction
The study of cooperative interactions in bacteria is of interdisciplinary interest,
as it is relevant for understanding microbial community assembly (1, 2), the
establishment of infections (3-5) , and biotechnological processes (6). Bacteria
exhibit a wide range of cooperative traits, including the formation of biofilms
and fruiting bodies, the secretion of toxins to infect hosts, coordinated swarm-
ing, and the scavenging of nutrients from the environment through the secre-
tion of shareable compounds, such as enzymes and siderophores (7,8). While
the existing body of work has greatly changed our perception of bacteria - from
simple autarkic individuals to sophisticated organisms, interacting and coop-
erating with each other - there are still considerable knowledge gaps. For in-
stance, many of the insights gained on the sharing of public goods are based
on experiments in planktonic batch cultures, where behavioural responses are
averaged across millions of cells. This contrasts with the natural lifestyle of
bacteria, where individual cells adhere to surfaces and form biofilms, and pri-
marily interact with their immediate neighbours at the micrometre scale (9,10).
The mismatch between laboratory and natural conditions has led to controver-
sies in the field regarding the general relevance of microbial cooperation (11-13).
In our paper, we tackle these issues by testing whether and to what extent
secreted siderophores are shared between surface-attached individuals of the
bacterium Pseudomonas aeruginosa using fluorescent microscopy. Sideropho-
res are secondary metabolites produced by bacteria to scavenge iron from the
environment, where it typically occurs in its insoluble ferric form or is actively
withhold by the host in the context of infections (14, 15).In our experiments, we
examined the production and secretion of pyoverdine, the main siderophore of
P. aeruginosa (16). Pyoverdine production has become a model trait to study
cooperation in bacteria, because it fulfils all the criteria of a cooperative trait:
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it is costly to produce and secreted outside the cell, where it generates bene-
fits in iron-limited media for the producer itself, but also for nearby individu-
als with a compatible receptor (17â€“19). Although highly influential, many of
the insights gained are based on batch culture experiments, which tell us lit-
tle about whether pyoverdine is also shared in surface-attached communities,
where molecule diffusion might be limited, and thus the range of sharing con-
strained (13, 20). However, such knowledge is key to understand whether pub-
lic goods cooperation occurs in natural settings and in infections, where bacteria
typically live in biofilms attached to organic and inorganic substrates (8, 21).
Here, we present data from fluorescence time-laps microscopy experiments that
examined bacterial interactions in real time at the micrometer scale. First, we
tested whether pyoverdine molecules, secreted by producing cells, reach indi-
viduals that cannot produce pyoverdine themselves but have the receptor for
uptake. Such evidence would be a direct demonstration of molecule sharing.
Second, we test whether pyoverdine serves as a signalling molecule (22), al-
lowing producers to respond to changes in their social neighbourhood. Specifi-
cally, we predict that lower pyoverdine investment is required in a cooperative
neighbourhood due to the efficient reciprocal pyoverdine sharing. Conversely,
non-producers, which act as a sink for pyoverdine, should trigger increased in-
vestment levels to compensate for pyoverdine loss (23,24). Third, we examined
whether pyoverdine diffusivity limits the range across which pyoverdine can be
efficiently shared. To this end, we manipulated both the media viscosity, which
directly affects molecule diffusion, and the distance between producer and non-
producer cells, which increases the diffusion time and reduces the amount of
pyoverdine reaching non-producers. Finally, we used time-laps microscopy to
quantify fitness effects of pyoverdine production and sharing in growing micro-
colonies. Taken together, our experiments shed light on the physical boundaries
and individual fitness consequences of public goods sharing.
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Results
Pyoverdine diffuses from producer to non-producers
We put mono- and mixed cultures of the wildtype strain PAO1 and its iso-
genic pyoverdine mutant PAO1 ∆pvdD (tagged with a fitness-neutral mCherry
marker) on iron-limited agarose pads on a sealed microscopy slide. Cultures
were highly diluted such that single cells were physically separated from each
other at the beginning of the experiment. We then monitored the pyoverdine
fluorescence in growing micro-colonies over time for both strains under the mi-
croscope. Pyoverdine fluorescence becomes visible in the periplasma, where
molecule maturation occurs (13, 32) (figure 1b). We found that fluorescence
in non-producer colonies was indistinguishable from background signal one
hour after incubation, indicating that no detectable pyoverdine had yet been
taken up (figures 1a+c and S1). However, pyoverdine fluorescence in non-
producer cells significantly increased over time in mixed cultures (LM: F5,7567
= 913, p < 0.001) was significantly higher than the background fluorescence in
non-producers growing as monocultures (t-test: t3945 = 79.33, p < 0.001, figures
1a+d and S1). This demonstrates that significant amounts of pyoverdine dif-
fuse from producer to non-producer microcolonies even when there is no direct
cell-to-cell contact.
Producers alter pyoverdine investment in the presence of
non-producers
To test whether producers respond to changes in their social environment, we
followed the expression pattern of pvdA (a gene involved in pyoverdine synthe-
sis) and natural pyoverdine fluorescence in growing producer microcolonies
(figures 2 and S2). In our control treatment with added iron, both pvdA and
pyoverdine signal were downregulated compared to iron-limited conditions,
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demonstrating the functioning and high sensitivity of our reporters. Under
iron limitation, meanwhile, pvdA-expression was significantly higher in mixed
compared to monoculture at one hour (t-test: t115 = 5.23, p < 0.001) and three
hours (t860 = 13.92, p < 0.001) post-incubation (figures 2a and S2a). Pyoverdine
fluorescence mirrored pvdA expression patterns, with higher pyoverdine lev-
els being detected in producer cells growing in mixed cultures (figures 2b and
S2b), although the difference was only significant after three hours (t-test: t992
= 13.30, p < 0.001), but not after one hour (t-test: t88 = 1.26, p = 0.211). The
picture changed five hours post-incubation, where both pvdA-expression and
pyoverdine fluorescence were significantly lower in mixed compared to mono-
cultures (pvdA-expression: t6441 = -16.67, p < 0.001; pyoverdine fluorescence:
t6017 = -50.01, p < 0.001). These analyses demonstrate that producers rapidly
alter pyovedine investment in response to the presence of non-producers.
Pyoverdine non-producers outgrow producers in mixed
cultures
After having established that pyoverdine is shared between neighbouring, yet
physically separated surface-attached microcolonies, we explored the fitness
consequences of pyoverdine sharing. This is important because experiments
in liquid batch cultures repeatedly revealed that non-producers can outcom-
pete producers, by saving the cost of pyoverdine production, yet exploiting
the siderophores produced by others, a phenomenon that is called "cheating"
(17, 33-36). To examine whether cheating is also possible when bacteria grow
as surface-attached microcolonies, we grew producers and non-producers in
mono and mixed culture and followed microcolony growth dynamics over time
(figure 3). Control experiments in iron-supplemented media revealed that all
strains grew equally well regardless of whether they grew in mono or mixed
cultures (figure S4). In iron-limited media, however, we found that microcolony
growth was significantly reduced for non-producers compared to producers
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(growth rate: t23= -10.57, p < 0.001, figure 3e; cell number: t23= -10.27, p < 0.001,
figure 3g). This shows that the inability to produce pyoverdine is a major hand-
icap in iron-limited media.
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Figure 1: Pyoverdine is taken up by non-producing cells in a time-dependent manner, demonstrating
pyoverdine sharing between physically separated, surface-attached microcolonies of P. aeruginosa. (a)
Time-course measures on natural pyoverdine fluorescence units (RFU) shows constant background flu-
orescence in non-producer cells grown in monocultures (filled squares), whereas pyoverdine fluorescence
significantly increased in non-producer cells grown in mixed cultures with producers (open squares).
Mean relative fluorescence values ± standard errors are scaled relative to producer monocultures after
one hour of growth. Representative microscopy pictures show pyoverdine fluorescence in a producer mi-
crocolony (b), a non-producer colony from a monoculture (c), and a non-producer colony from a mixed
culture (d). Important to note is that only apo-pyoverdine (i.e. iron-free pyoverdine) is fluorescent, and
therefore the measured fluorescence intensities represent a conservative measure of the actual pyoverdine
content per cell. Furthermore, the fluorescence intensity in producer cells is always higher than in non-
producer cells because it represents the sum of pyoverdine uptake and newly synthesized pyoverdine,
whereas for non-producers, fluorescence represents pyoverdine uptake only.
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Figure 2: Producer cells adjust their pyoverdine investment level in response to changes in the social
environment. (a) Time-course data show that pvdA, a gene encoding an enzyme involved in pyoverdin
synthesis, is down-regulated in iron-rich media (grey diamonds), but up-regulated in iron-deplete media.
Importantly, producers exhibited different pvdA expression patterns depending on whether they grew
together with non-producers (open circles) or as monoculture (filled circles). While producers showed
increased gene expression in mixed compared to monoculture after one and three hours, the pattern flipped
after five hours. (b) The same qualitative pattern was observed when measuring pyoverdine content
per cell, as relative fluorescence units (RFU). Fluorescence values are scaled relative to the producer
monocultures after one hour of growth. Error bars indicate standard errors of the mean.
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Figure 3: Growth performance of surface-attached microcolonies of pyoverdine producers (filled squares)
and non-producers (open squares) of P. aeruginosa in monocultures (left column) and mixed cultures
(right column). While pyoverdine non-producers show growth deficiencies in monoculture, due to their
inability to scavenge iron, they outcompete the producers in mixed cultures. This growth pattern shows
that non-producers save costs by not making any pyoverdine, yet gain fitness benefits by capitalizing
on the pyoverdine secreted by the producers. (a) and (b) show representative microscopy pictures for
monocultures and mixed cultures, respectively. The overall growth trajectories of producers and non-
producers differ substantially between monocultures (c) and mixed cultures (d). While producers had a
significantly higher growth rate (e) and grew to higher cell numbers (g) in monocultures, the exact oppo-
site was the case in mixed cultures for both the growth rate (f) and cell number (h). Growth parameters
are given relative to the producers in monoculture. Asterisks indicate significant differences and error
bars denote standard errors of the mean.
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This fitness pattern diametrically flipped in mixed cultures, where non-producer
microcolonies grew significantly faster (t35= 2.64, p = 0.012, figure 3f) and to
higher cell numbers (t31 = 2.48, p = 0.019, figure 3h) than producer microcolonies.
Intriguingly, non-producers experienced a relative fitness advantage between
hours one and three (t-test: t20 = 4.53, p < 0.001), but not at later time points (t41
= -0.184, p = 0.855; figure S5). This specific period, at which the relative fitness
advantage manifests, perfectly matches the timeframe during which producers
exhibited highest pvdA expression levels, and non-producers started accumu-
lating pyoverdine (figure 2 and S2). Our findings thus provide a direct tem-
poral link between the high costs of pyoverdine investment to producers, the
increased benefits accruing to non-producers, and the resulting opportunity for
non-producers to act as cheaters and to successfully outcompete producers.
The physical boundaries of pyoverdine sharing and benefits
for non-producers
The above experiments revealed that pyoverdine can be shared between two
physically separated microcolonies when grown in the same field of view (128
x 96 µm) under the microscope (average ± SD distance between cells d = 36.2
± 18.2 µm). Next, we asked what the physical limit of pyoverdine sharing
is. We thus repeated to above experiment, but this time we focussed on non-
producer cells that had no producer cell within the same field of view, but only
a more distant producer in an adjacent field of view (minimal distance d = ca.
100 µm). Under these conditions, we found that non-producers benefited from
the presence of more distant producers in the same way as they benefited from
the presence of a close producer (figure 4a+b; significantly increased growth of
non-producers in mixed culture, for d = ca. 100 , t-test: t14 = 4.02, p = 0.001).
However, contrary to the previous observation (figure 4a), the producer no
longer experienced a significant growth reduction in the presence of a more
distant non-producer (figure 4b, for d = ca. 100 µm, t9 = -0.80, p = 0.442). We
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Figure 4: The relative fitness advantage of pyoverdine non-producers in mixed cultures is dependent on
the distance between producer (grey) and non-producer (white) microcolonies. In monoculture assays,
the non-producers had significantly lower number of doublings than the producers in all experiments. In
mixed cultures, meanwhile, the number of doublings of non-producers significantly increased when the
producer microcolony was (a) within the same field of view (average distance between cells 36 µm), (b)
in an adjacent field of view (minimal distance ca. 100 µm), but not when producers were far away (on
opposite ends of the agarose pad) (c). These analyses show that pyoverdine can be shared and exploited
across a relatively large distance. Boxplots represent the median with 25th and 75th percentiles and
whiskers show the 1.5 IQR.
then expanded the distance between non-producers and producers even fur-
ther by adding the two strains on opposite ends of a double-sized agarose pad.
In contrast to the previous results, this assay revealed that non-producers had
significantly lower number of doublings in both mixed (t13= -2.41, p = 0.032)
and monocultures (t9= -4.66, p = 0.001) (figure 4c), suggesting that pyoverdine
diffusion and sharing is disabled across this large distance in the time frame
analysed.
In addition, our microscopy experiment revealed that pyoverdine sharing did
not only affect the doubling rate of cells but also their size (figure S6). While
non-producer cells were significantly smaller than producer cells in monocul-
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Figure 5: Pyoverdine sharing is impeded on hard surfaces. While the previous experiments showed
that pyoverdine is extensively shared between neighbouring microcolonies on relatively soft surfaces (1%
agarose), efficient sharing was no longer possible on hard surfaces (2% agarose) even when non-producers
(open squares) were located within the same field of view (filled squares). Boxplots represent the median
with 25th and 75th percentiles and whiskers show the 1.5 IQR
ture (LM: F1,1294 = 150.90, p < 0.001, measured three hours post-incubation), the
cell size of non-producers significantly increased when grown together with a
nearby producing neighbour (same field of view d = ca. 36 µm: t446 = 10.24, p
< 0.001, figure S6 a; adjacent field of view d = ca. 100 µm: t161 = 4.10, p < 0.001,
figure S6 b), but not when producers were far away (on opposite ends of the
agarose pad: t263= 0.45, p = 0.660, figure S6 c).
While the above experiments examined pyoverdine sharing on 1% agarose
pads - a solid yet still moist environment - we were wondering whether py-
overdine sharing is also possible on much harder and drier surfaces. To test
this possibility, we repeated the growth experiments on 2% agarose pads. Un-
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der these conditions, we observed that non-producers no longer benefited from
growing next to producers (no significant difference in the doubling numbers
between mono and mixed cultures: t14 = -0.98, p = 0.346) (figure 5). This finding
is compatible with the view that molecule diffusion is much reduced on very
hard surfaces, preventing pyoverdine sharing between adjacent microcolonies.
Discussion
Our single-cell analysis on pyoverdine production in P. aeruginosa provides
several novel insights on the social interaction dynamics between surface-attached
bacteria. First, we found that pyoverdine secreted by producer cells is taken
up by physically separated non-producer cells, thereby directly demonstrat-
ing pyoverdine sharing. Second, we discovered that producer cells rapidly
adjust pyoverdine expression levels when non-producers are nearby, by first
up-regulating and then down-regulating pyoverdine investment. Third, we
demonstrate that pyoverdine sharing has fitness consequences, as it boosts the
growth and cell size of non-producers when growing in the vicinity of produc-
ers. Finally, we explored the physical limits of pyoverdine sharing and show
that on soft surfaces, pyoverdine can be shared across a considerably large scale
(at least 100 µm, i.e. ca. 50 times the length of a bacterium), whereas efficient
sharing is impeded with larger distances between cells and on hard surfaces.
Altogether, our experiments suggest that public goods sharing and exploitation
can take place between surface-attached bacteria across a wide range of natu-
rally relevant conditions, and is mediated by molecule diffusion without the
need for direct cell-to-cell contact.
Our results oppose previous work claiming that pyoverdine is predominantly
shared between adjacent cells within the same microcolony (13). This claim has
provoked a controversy on whether pyoverdine, and secreted compounds in
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general, can indeed be regarded as public goods (12, 37). The difference be-
tween our experiments and the ones performed by Julou et al. (13) is that their
study solely examined pyoverdine content of cells within the same microcolony.
Unlike in our study, there was no direct test of whether pyoverdine diffuses to
neighbouring microcolonies and what the fitness consequences of such diffu-
sion would be. While we agree that a considerable amount of pyoverdine is
probably shared within the microcolony, we here demonstrate that a significant
amount of this molecule also diffuses out of the microcolony, providing signifi-
cant growth benefits to physically separated neighbouring microcolonies. Thus,
our work concisely resolves the debate by showing that secreted hydrophilic
compounds, such as pyoverdine (38), can be considered as public goods, even
in structured environments, with the amount of sharing and the associated fit-
ness consequences being dependent on the distance between neighbouring mi-
crocolonies. Moreover, the distance effect we report here at the single-cell level
is in line with density effects described at the community level, where secreted
compounds are predominantly shared and become exploitable at higher cell
densities (i.e. when cell-to-cell distance is reduced 39-42).
A key advantage of single-cell analyses is that they allow the tracking of bac-
terial behavioural and growth changes in real time with high precision, im-
mediately after the start of an experiment. This contrasts with batch culture
experiments, where responses can only be measured after several hours, once
the proxies for responses (e.g. optical density) become detectable at the popu-
lation level. For instance, results from previous batch-culture studies suggest
that pyoverdine producers seem to overinvest in pyoverdine when grown to-
gether with non-producers (23, 24). However, the interpretation of these results
were based upon a number of assumptions, and the batch-culture approach pre-
cluded an in-depth analysis of the temporal pattern and consequences of such
overinvestment. Our analysis now provides a nuanced view on the interactions
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between producers and non-producers. We could show that soon after the in-
oculation of bacteria on the agarose pad, producers started overexpressing py-
overdine (figures 2 and S2), which coincided with pyoverdine accumulation in
non-producer cells (figures 1 and S1), and significant fitness advantages to non-
producers (figure S5). Moreover, our findings indicate the that producers can
possibly respond to exploitation by down-regulating pyoverdine production at
later time points, a response that correlated with the abolishment of further fit-
ness advantages to non-producers.
Our considerations above raise questions regarding the regulatory mechanisms
involved in controlling the observed expression changes. Molecular studies
suggest that pyoverdine serves as a signalling molecule regulating its own pro-
duction (22, 43). Specifically, when iron-loaded pyoverdine binds to its cog-
nate receptor FpvA, a signalling cascade is triggered, which results in the re-
lease of PvdS (the iron-starvation sigma factor, initially bound to the inner cell
membrane by the anti-sigma factor FpvR). PvdS then upregulates pyoverdine
production. This positive feedback, triggered by successful iron uptake, is op-
posed by a negative feedback operated by Fur (ferric uptake regulator), which
silences pyoverdine synthesis once enough iron has been taken up (16, 44). Our
results can be interpreted in the light of these feedbacks, given that the rela-
tive strength of the opposing feedbacks determines the resulting pyoverdine
investment levels (45). For example, producer micro-colonies reach higher cell
densities in mono-compared to mixed cultures (figure 3, after 3h: 13.2 ± 2.3
versus 6.7 ± 1.3 cells; after 5h: 122.7 ± 17.9 versus 55.0 ± 8.1 cells, respec-
tively). Higher cell densities likely lead to more efficient pyoverdine sharing,
which supposedly stimulates both pyoverdine-signalling and iron uptake. Pos-
itive and negative feedback should thus be in balance and result in an inter-
mediate pyoverdine investment levels. Conversely, when producers grow in
mixed cultures then cell density is reduced and non-producers serve as a sink
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for pyoverdine, thereby reducing iron supply to producers. In this scenario, the
positive feedback should be stronger than the negative feedback, resulting in
the upregulation of pyoverdine. While these elaborations are compatible with
the pyoverdine expression patterns observed at hour one and three, the flip in
expression patterns between mono and mixed cultures after five hours is more
difficult to explain. One option would be that the previously described switch
from pyoverdine production to recycling (46â€“48) occurs earlier in mixed than
in monocultures. An alternative option would be that producers can recognize
the presence of exploitative cheaters and downscale their cooperative efforts ac-
cordingly.
Our results showing that non-producers can outcompete producers in mixed
cultures, even when microcolonies are physically separated, confirms predic-
tions from social evolution theory for microbes (49-52). One key condition re-
quired for cooperation to be maintained is that cooperative acts must be more
often directed towards other cooperators than expected by chance. This interac-
tion probability is measured as the degree of relatedness r, a parameter central
to inclusive fitness theory (53, 54). Traditionally, high relatedness has been as-
sociated with the physical separation of cooperators and non-cooperators into
distinct patches (54). Our results now show that this traditional view is not nec-
essarily applicable to public goods cooperation in bacteria, because the physical
separation of pyoverdine producers and non-producers is insufficient to pre-
vent exploitations and maintain cooperation (figure 3). Clearly, relatedness in
our scenario should be measured at the scale at which pyoverdine sharing can
occur (50), which exceeds the boundaries of a single microcolony. Thus, in sce-
narios where microbial cells are immobile, it is the diffusion properties of the
public good that determines the degree of relatedness between interacting part-
ners (49, 51).
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In summary, our findings on pyoverdine sharing and exploitation between phys-
ically separated microcolonies has broad implications for our understanding
of the social life of bacteria in many natural settings. This is because bacteria
typically live in surface-attached communities in aquatic and terrestrial ecosys-
tems, as well as in infections (8, 21). Many of these natural habitats feature soft
surfaces, as mimicked by our experimental set up, making the diffusion and
sharing of secreted compounds between cells highly likely. However, our work
also reveals physical limits to public goods cooperation, namely on hard sur-
faces, where public good diffusion and sharing is impeded. This shows that
whether or not a secreted compound is shared is context-dependent (38), and
relies, amongst other factors, on the physical properties of the environment.
Materials and Methods
Strains and media
Our experiments featured the clinical isolate P. aeruginosa PAO1 (ATCC 15692),
and its clean pyoverdine knock-out mutant (PAO1∆pvdD)., directly derived
from this wildtype. To be able to distinguish the two strains, we used fluores-
cent variants of these strains constructed via chromosomal insertion (attTn7::ptac-
gfp, attTn7::ptac-mcherry) - i.e. PAO1-gfp, PAO1-mcherry, PAO1∆pvdD-gfp and
PAO1∆pvdD-gfp. A preliminary experiment revealed that these fluorescent mark-
ers did not affect the growth performance of the strains (Figure S2). For our gene
expression experiments, we used the reporter strain PAO1pvdA-gfp (chromoso-
mal insertion: attB::pvdA-gfp) (Kaneko et al. 2007). PvdA catalyses an impor-
tant step in the biosynthesis pathway of pyoverdine (Leoni et al. 1996), and its
expression level is therefore a good proxy for the investment into pyoverdine
production.
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Overnight cultures were grown in 8 mL Lysogeny Broth (LB) medium in 50 mL
Falcon tubes, and incubated at 37 ◦C, 200 rpm for 16-18 hours. Cells were then
harvested by centrifugation at 3000 rpm for 3 minutes and resuspension in 8 mL
of 0.8% NaCl (saline solution). For all experiments, we subsequently diluted
the washed cultures in saline solution to an OD = 1 (optical density at 600 nm).
For all microscopy experiments, we used CAA medium (per liter: 5 g casamino
acids, 1.18 g K2HPO4 ·3H2O, 0.25 g MgSO4 ·7H2O). To create severe iron limi-
tation, we added the chemical iron chelator 2,2-Bipyridine (final concentration
40 µM). To create iron-replete conditions, we added 200 µM FeCl3. All chemi-
cals were purchased from Sigma-Aldrich (Buchs SG, Switzerland).
Preparation of microscopy slides
We adapted a method previously described in (de Jong et al. 2011). Standard
microscopy slides (76 mm x 26 mm) were washed with EtOH and dried in a
laminar flow. We used 65 µL “Gene Frames” (Thermo Fisher Scientific) to pre-
pare agarose pads. Each frame features a single chamber of 0.25 mm thickness
(1.5 cm x 1.6 cm) and 65 µL volume. The frame is coated with adhesives on both
sides so that it sticks to the microscopy slide, and at the same time adheres the
cover glass from the top. The sealed chamber is airproof, which is necessary to
prevent evaporation and deformation of the pad during the experiment.
To prepare microscopy pads, we heated mL CAA supplemented with agarose
(1% unless indicated otherwise) in a microwave. The melted agarose-media
mix was subsequently cooled to approximately 50 ◦C. Next, we added the sup-
plements: either 2,2-Bipyridine (final concentration 450 µM) or FeCl3 (final con-
centration 200 µM) to create iron-limited or iron-replete conditions, respectively.
We pipetted 360 µL of the agarose solution into the gene frame and immediately
covered it with a cover glass. The cover glass was pressed down with a gentle
pressure to dispose superfluous media. After the solidification of the agarose
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pad (ca. 30 minutes), we removed the cover glass (by carefully sliding it side-
ways) and divided the original pad into 4 smaller pads of equal size by using a
sterile scalpel. The further introduced channels between pads, which served as
a reservoir for oxygen. We then put 1 µL of highly diluted bacterial culture (OD
= 1 culture diluted by 2.5*104) in the middle of each pad. Two pads were inoc-
ulated with a 1:1 mix of pyoverdine producers and non-producers, whereas the
other two pads were inoculated with a monoculture (either producer or non-
producer). After the inoculum drop had evaporated, we sealed the pads with a
new cover glass using the adhesive of the Gene Frame. With this protocol, we
managed to create agarose pads with consistent properties across experiments.
Microscopy setup and imaging
All experiments were carried out at the Center for Microscope and Image Anal-
ysis of the University Zürich (ZMB) using a widefield Leica DMI6000 micro-
scope. The microscope featured a plan APO PH3 objective (NA = 1.3), an au-
tomated stage and an auto-focus. For fluorescent imaging, we used a Leica L5
filter cube for GFP (Emission: 480 nm ± 40 nm, Excitation: 527 nm ± 30 , DM =
505) and a Leica TX2 filter cube for mCherry (Emission: 560 nm ± 40 nm, Exci-
tation: 645 nm ± 75 nm. Auto-fluorescence of pyoverdine was captured with a
Leica CFP filter cube (Emission: 436 nm ± 20 nm, Excitation: 480 nm ± 40 nm,
DM = 455). We used a Leica DFC 350 FX camera (resolution: 1392x1040 pixels)
for image recording (16 bit colour depth).
Image processing and blank subtraction
To extract information (cell size, fluorescence) from every single cell, images
had first to be segmented. Segmentation is the process of dividing an image
into objects and background. Since it is currently a bottleneck for high through-
put image analysis (Van Valen et al. 2016), we developed a new workflow
(see attached protocol for details). This workflow includes a protocol for the
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rapid, reliable and fully automated image segmentation without the need for
any priors (i.e. information on cell size and shape) and manual corrections. The
workflow starts with the machine learning, supervised object classification and
segmentation tool ilastik (Sommer et al. 2011). Ilastik features a self-learning al-
gorithm that autonomously explores the parameter space for object recognition.
We used a low number of phase contrast images from our experiments to train
ilastik for bacterial cell recognition and segmentation. Each training round is
followed by user inputs regarding segmentation errors. These inputs are then
incorporated in the next training round, until segmentation is optimized and
error-free. Once the training is completed, microscopy images from all exper-
iments can be fed to ilastik and segmentation is then carried out in a fully au-
tomated manner, without the need for any further manual corrections. Ilastik
produces binary images as an output (black background vs. white objects).
For image analysis, this output was then transferred to Fiji, a free scientific im-
age processing software package (Schindelin et al. 2012). We wrote specific
macro-scripts in Fiji to fully automate the simultaneous analysis of multiple
single-cell features such as cell size, shape, fluorescence, etc. First, we used the
binary images to create an overlay of region of interests for every single cell,
which could then be used in a second step to measure bacterial properties from
phase contrast and fluorescence images (see supplementary material for a step-
by-step protocol). Next, we applied a pixel-based blank correction procedure in
Fiji, to obtain unbiased fluorescence intensities for each cell. For each agarose
pad and time point, we imaged four empty random positions on the agarose
pad without bacterial cells and averaged the grey values for each pixel. The
averaged grey value of each pixel was than subtracted from the correspond-
ing pixel position in images containing cells. This pixel-based blank correction
accounts for intensity differences across the field of view caused by the optical
properties of the microscope (vignetting). In the experiments where we simulta-
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neously measured pvdA-gfp expression and pyoverdine fluorescence, we had
to further correct for the leakage of pyoverdine signal into the GFP-channel.
To do so, we imaged cells of the unmarked wildtype strain, which produced
pyoverdine but had no GFP reporter. We then measured the pyoverdine sig-
nal in the GFP-channel at three different time points (one, three and five hours
post-incubation), and then used these values to blank correct the fluorescence
intensities in cells with the pvdA-gfp reporter.
Assays measuring pvdA expression and pyoverdine
fluorescence
To monitor pyoverdine investment by producer cells and pyoverdine uptake by
non-producer cells, we quantified natural pyoverdine fluorescence in bacterial
micro-colonies of both strains in mixed and monocultures over time. For pro-
ducer micro-colonies we further measured pvdA expression levels over time.
Because the excitation wavelength for pyoverdine fluorescence overlaps with
the UV range, the high exposure time required to measure natural pyoverdine
fluorescence induces damage (i.e. phototoxicity) to bacterial cells. Accordingly,
each bacterial micro-colony could only be measured once. To obtain time course
data for pyoverdine expression and uptake levels, we thus prepared multiple
microscopy slides, as described above, and incubated them at 37 ◦C in a static
incubator. At each time step (one, three and five hours post incubation), we
then processed two slides for imaging. Exposure time for measuring GFP-
fluorescence was 800 ms and for pyoverdine 1500 ms, with a (halogen) lamp
intensity of 100%. To guarantee reliable automated image analysis, we only
considered positions that were free from non-bacterial objects (e.g. dust) and
where all cells laid within one focus layer. Focus was adjusted manually. We
recorded at least five positions per treatment, time point and slide. The experi-
ment was carried out twice, in two completely independent batches.
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Fitness Assay
We used time-laps microscopy to measure the growth performance of pyover-
dine producer cells (tagged with mCherry) and non-producer cells (tagged with
GFP) in mixed and monoculture. As described above, we cut the agarose pad
in four patches and inoculated two patches with a 1:1 mix of producers and
non-producers, and one patch each with a monoculture. We then chose 20
positions (five per patch) that contained two separated cells (one cell of each
strain for mixed cultures and two cells of the same type for monocultures), and
imaged these positions sequentially every 15 minutes over 5 hours, using the
automated stage function of the microscope. Following a position change and
prior to imaging, we used the auto-focus function of the microscope to adjust
the z-position in order to keep cells in focus. This protocol allowed us to follow
the growth of micro-colonies from a single-cell stage.
We carried out the above fitness assays across a range of different conditions.
In a control experiment, we added 200 µM FeCl3 to the agarose pad to study
the strain growth in the absence of iron limitation. Since bacteria grow very
well in iron-replete media, we stopped the imaging after three hours before
micro-colonies started to grow in multiple layers. Next, we monitored strain
growth on iron-limited 1% agarose pads supplemented with 450 µM bipyridin.
To examine whether pyoverdine sharing and fitness effects depend on the dis-
tance between two cells, we performed fitness assays where two cells were po-
sitioned: (i) close to one another in the same field of view (average distance
between cells 36.21 µm ± 18.17 SD); (ii) further apart in adjacent fields of view
(with an estimated minimum distance of 96 µm, given the field of view size of
96 µm x 128 µm); and (iii) far from one another. This latter condition was cre-
ated by adding the two strains on opposite ends of an elongated double-sized
agarose pad. Finally, we repeated the growth assays in media with increased
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viscosity (i.e. on 2% agarose pads).
Statistical methods
All statistical analyses were performed in R 3.3.0 (31) using linear models (ANOVA
or t-tests). Prior to analysis, we used the Shapiro-Wilk test to check whether
model residuals were normally distributed. Since each experiment was carried
out in multiple independent experimental blocks, we scaled values within each
block relative to the mean of the control treatment (i.e. pyoverdine producer
monocultures). For all time-laps growth experiments, we considered the posi-
tion (i.e. the field of view) as the level of replication. For the analysis of single
cell fluorescence data, we considered each cell as a replicate.
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Figure S1: Pyoverdine is taken up by non-producing cells in a time-dependent manner, demonstrating 
pyoverdine sharing between physically separated, surface-attached micro-colonies. Time-course 
measures on natural pyoverdine fluorescence units (RFU) shows constant background fluorescence in 
non-producer cells grown in monocultures (orange squares), whereas pyoverdine fluorescence 
significantly increased in non-producer cells grown in mixed cultures with producers (blue squares). 
Mean relative fluorescence values ± standard errors are scaled relative to producer monocultures after 
one hour of growth. Important to note is that only apo-pyoverdine (i.e. iron-free) is fluorescent, and 
therefore the measured fluorescence intensities represent a conservative measure of the actual 
pyoverdine content per cell. Furthermore, the fluorescence intensity in producer cells is always higher 
than in non-producer cells because it represents the sum of pyoverdine taken up from the environment 
and newly synthesized pyoverdine, whereas for non-producers, fluorescence represents pyoverdine 
uptake only. 
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Figure S2: Producer cells adjust their pyoverdine investment level in response to changes in the social 
environment. (a) Time-course data show that pvdA, a gene encoding an enzyme involved in pyoverdin 
synthesis, is down-regulated in iron-rich media (grey squares), but up-regulated in iron-deplete media. 
Importantly, producers exhibited different pvdA expression patterns depending on whether they grew 
together with non-producers (blue squares) or as monoculture (orange squares). While producers 
showed increased gene expression in mixed compared to monoculture after one and three hours, the 
pattern flipped after five hours. (b) The same qualitative pattern was observed when measuring 
pyoverdine content per cell, as relative fluorescence units (RFU). Fluorescence values are scaled 
relative to the producer monocultures after one hour of growth. Important to note is that only apo-
pyoverdine (i.e. iron-free) is fluorescent. Error bars indicate standard errors of the mean.  
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Figure S3: Growth did not differ between strains tagged with GFP or mCherry. We grew the wildtype 
PAO1 strain, either tagged with GFP or mCherry, on iron-limited agarose pads and calculated the 
number of doublings over 5 hours. Doubling numbers did not significantly differ between the two strains 
(t-test: t94 = 1.14, p = 0.258). Thus, we can be confident that growth differences observed in our 
experiments are due to biological and not tag effects. Symbols and error bars indicate means and 
standard errors of the mean, respectively. 
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Figure S4: There are no growth differences between the pyoverdine-producing strain (filled squares) 
and the non-producing strain (open squares) on agarose pads supplemented with 200 µM FeCl3. Growth 
of the two strains was neither different in monoculture (t-test: t78 = -1.61, p = 0.11) nor in mixed culture 
(t-test: t71 = -0.23, p = 0.82). These results are in line with the view that pyoverdine production is 
completely stalled when iron is plentiful (46), such that there is no more difference in the strains’ 
phenotype. This also means that the fitness effects we observed in iron-depleted media (Figures 3 - 6) 
are attributable to pyoverdine-mediated social interactions. The number of doublings was calculated 
over a growth period of 3 hours. Symbols and error bars indicate means and standard errors of the mean, 
respectively. 
5 The Physical Boundaries of Public Goods Cooperation Between
Surface-Attached Bacterial Cells
101
6 
 
Figure S5: Non-producers experience a significant relative fitness advantage during the first three 
hours of competition (zero to three hours; one sample t-test: t20 = 4.53, p < 0.001), but not during the 
later competition phase (three to five hours; one sample t-test: t41 = -0.18, p = 0.85). We used cell 
numbers to calculate strain frequencies at time point zero, three and five hours and to estimate the 
relative fitness of non-producers as v = [q2(1 – q1]/[q1(1 – q2], where q1 and q2 are the initial and final 
frequencies of the non-producer (Ross-Gillespie et al. 2007)a. The dotted line represents the fitness 
equilibrium, where no strain has a relative fitness advantage over the other. Symbols and error bars 
indicate means and standard errors of the mean, respectively. 
 
  
                                                     
a Ross-Gillespie A, Gardner A, Buckling A, West SA, Griffin AS. Frequency dependence and cooperation: 
theory and a test with bacteria. Am Nat. 2007;170(3):242–331. DOI: 10.1086/519860 
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Figure S6: Pyoverdine sharing affects cell size. While non-producer cells (open squares) were 
significantly smaller than producer cells (closed squares) in monocultures, non-producer cell size was 
restored to wildtype level in mixed cultures when the producer microcolony was (a) within the same 
field of view (average distance between cells 36 µm), (b) in an adjacent field of view (minimal distance 
~ 100 µm), but not when producers were far away (on opposite ends of the agarose pad) (c). Cell size 
was measured after three hours of growth. Error bars indicate the standard error of the mean. 
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1 General Information
This document presents a new workflow for automated segmentation of bacterial cells, and the
subsequent analysis of single-cell features (e.g. cell size, relative fluorescence values). The described
methods require the use of three freely available open source software packages. These are:
1. ilastik: http://ilastik.org/ [1]
2. Fiji: https://fiji.sc/ [2]
3. R: https://www.r-project.org/ [4]
Ilastik is an interactive, machine learning based, supervised object classification and segmentation
toolkit, which we use to automatically segment bacterial cells from microscopy images. Segmenta-
tion is the process of dividing an image into objects and background, a bottleneck in many of the
current approaches for single cell image analysis. The advantage of ilastik is that the segmentation
process does not require priors (e.g. information on cell shape), and can thus be used to analyze any
type of objects. Furthermore, ilastik also works for low-resolution images. Ilastik involves a user
supervised training process, during which the software is trained to reliably recognize the objects of
interest. This process creates an ”Object Prediction Map” that is used to identify objects in images
that are not part of the training process. The training process is computationally intensive. We thus
recommend to use of a computer with a multi-core CPU (ilastik supports hyper threading) and at
least 16GB of RAM-memory. Alternatively, a computing center or cloud computing service could
be used to speed up the training process. The training process, although time consuming, has to
be carried out only once. Afterwards, the trained classifier is applicable to all experiments with the
same type of objectives.
Segmentation is then followed by high throughput extraction of cell parameters in Fiji. For that
purpose, we developed specific macro scripts (see Fiji_scripts part1 - 5). We will explain the use of
these scripts in detail in the ”Walkthrough” section (4) below. The current version of the scripts are
adapted to work with the attached example files. It might be necessary to adjust them to the user’s
specific needs.
In a final step, the extracted cell parameter data will be important into a R-based graphical interface
called ShinyApp [5], which we specifically programmed for this workflow. This step is required be-
cause the information on cell parameters need to be connected to the descriptive variables (e.g. date,
time, image_ID, treatment, channel, etc.) of the experiment, which are at this stage only encrypted
in the file title. The ShinyApp is a user friendly interface and does not require knowledge of R pro-
gramming. Once this step is completed, a data set containing all analyzed images can be extracted
as a spread-sheet in csv-format, which can then be fed into any standard statistical software package
for in-depth analysis.
2 Methods Part I: Training of ilastik and Automated Segmen-
tation
It is beyond the scope of this document to provide detailed instructions on how to use ilastik. We
refer readers to the detailed instruction manuals available on http://ilastik.org. The docu-
mentations contain an in-depth descriptions of all the required steps (in ilastik), we briefly outline
below.
1
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2.1 Getting Started
In this step, we feed training pictures to ilastik and choose the starting conditions for the training
phase. To begin this process, we choose the “Pixel Classification + Object Classification” workflow.
Next, ilastik asks for training images, which should cover the full spectrum of variation observed
within an experiment (e.g. variation in cell numbers, contrast, cell size, etc.). We typically perform
segmentation based on phase contrast images, but it also works with bright field or fluorescence
images. In the next applet, we then select features that will be used to classify pixels (e.g. Colors,
Edges, Textures, etc.). It is advisable to start with a wide range (or even all) features, which can
subsequently be reduced if necessary.
All steps below should be repeated for all training images until object recognition is satisfactory (it
might be necessary to go back and forth between the images, especially if cell numbers differ). Now,
we are ready to launch the training process.
2.2 Training Procedure
In the training process we supervise the object classification in ilastik. Based on this manual clas-
sification, ilastik will create a so-called ”Object Prediction Map” that is later used for segmentation.
The training process should be performed in the ”Off-mode” , since the ”Live-Mode” is computationally
very expensive. To do so, toggle the button ”Live Update”. Training is in the ”Off-mode” when red circles
with a black crosses appear behind the label names.
1. Create two labels, one for the background and one for the objects.
2. Mark the background and the objects on the training images with the respective labels (Figure
1A & 2A: red = background, green = object).
3. To control the result, toggle to ”Live Update”. This option will compute the ”Object Prediction
Map”. If the object identification requires further improvement, toggle back to the ”Off-mode” and
repeat step 2.
4. Only applicable for low resolution/contrast images: To better distinguish the objects from the
background we can only mark the part of the cell with the highest contrast (Figure 1 B), which
is usually the center of the cell. This will improve object classification but also introduce a bias
in cell size. This bias can be corrected at a later stage (step 3.2; Figure 1C).
2.3 Thresholding Images Based on Object Classification
Step 2.2 creates an ”Object Prediction Map” that is now used to segment the image (result of seg-
mentation: Figure 2B). It might be necessary to switch back and forth multiple times between the
training and the thresholding mode to improve segmentation.
1. Set ”Input Channel” to the label you chose for the objects (e.g. Label 2 → Green → ”Input
Channel” = 1).
2. We set ”Sigma” to small values (e.g. 0.1). Sigma uses a Gaussian to smooth the ”Object Predic-
tionMap”, which is not necessarily needed. For details, please refer to the ilastik-documentation.
3. We choose an intermediate ”Threshold” (e.g. 0.5), in order to reliably segment the different
objects from one another. The threshold value allows us to change the size of the objects, which
are recognized as objects. Higher values indicate smaller objects an vice versa.
2
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Figure 1: (A) High resolution/contrast images. In the training process 2.2 we can mark the whole
cell with the ”Object Label” (green) since resolution is high enough to separate cells. (B) Low resolu-
tion/contrast. Only the center of the cell with high contrast level is marked with the ”Object Label”
(green). Resolution is not high enough to reliable separate cells, therefore we need to clearly separate
the cell with the ”background label” (thick red line). By only marking areas with high contrast level,
we introduces a bias in cell size, which can be corrected later. (C) Here we show a gfp-fluorescence
image, where the bias, introduced in (B), is already corrected (step 3.2). Outlines of the cells now
perfectly match the boarder of the cells. The possibility to correct for size bias allows us to reliably
segment images, even if the used camera resolution is poor (e.g. high sensitivity cameras)
4. We choose and appropriate ”Size Range” (e.g.10-1000000). This parameter is useful to exclude
non-biological objects such as dust particles.
5. By pressing ”Apply”, the threshold-settings are applied to the image (Figure 2B). Every object
should now be appear in a different color.
6. If the segmentation is satisfactorily the move to step 2.4. If an error is spotted, try to change
the threshold or go back to training mode.
2.4 From Segmentation to Objects
This step (”Object Feature Selection”) calculates the features of objects (Figure 2C). For details see
ilastik documentation.
1. Select ”All features”. The amount of calculated features can be reduced any stage.
2. Switch to the applet ”Object Classification”.
3. Create two labels, choose the ”Object Label” (green) and click on one cell to mark it.
4. Toggle ”Live Preview” to identify all objects.
2.5 Export Objects
These objects (from step 2.4) can now be exported (Figure 2D), as a binary black and white image.
1. Switch to the applet ”Object Information Export”
3
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Figure 2: (A) Objects (green) and background (red) were marked with the corresponding label (step
2.2 in ilastik). (B) Visualization of segmentation, based on the training procedure (step 2.3 in ilastik).
Every cell will appear with an individual color. If results are not satisfactory, either the threshold-
value has to be changed or cells have to be manually separated in the training step (2.2) (C) Based
on training and segmentation, ilastik predicts objects (step 2.4). (D) Predictions are exported as a
black and white image (here opened in Fiji; step 2.5). (E) This segmentation image can be used to
create regions of interest (ROIs; yellow outlines) in Fiji. (F) ROIs can than be used to measure cell
features in different images e.g. RFU in different channels.
2. Open export configuration by clicking on ”Choose Export Images Settings…”
3. ”Change Output File Info” to ”png” and save by clicking on ”OK”.
4. Press ”Export” to export one image. The exported Image will be saved in the folder, where the
example images are located. Ilastik will extend the original filename by ”_Object Prediction”.
5. As a quality control, we can now load a representative image into Fiji. If necessary adjust
contrast levels by applying ”Auto” (Image→Adjust→Threshold).
6. Check whether segmentation was successful (image should look like figure 2 D).
2.6 Automated Segmentation
If the ”Object Prediction” is successful and satisfactory, we can use the ”Batch Input”-function to
automatically apply the segmentation to all images in a folder.
4
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3 Methods Part II: Extracting Parameters from Single Cells
Now we switch to Fiji. Fiji is an image processing package to facilitate scientific image analysis,
based in ImageJ [3]. It is freely available under https://fiji.sc/. A step-by-step wlakthrough
for the following protocol can be found in section 4 (including example images).
Each of the following sections includes a short description of the implemented process, the Fiji-
commands needed to carry out the process on a single image, and information on how to automat-
ically apply the process to all images.
3.1 Thresholding Images in Fiji and Creating Uncorrected ROIS
In this step we will use the binary images received form ilastik to create regions of interests (ROIs),
which can later be use to extract cell parameters (e.g. length, RFU, etc.) from any type of image
(e.g. fluorescent images). To create ROIs we first have to threshold the binary images in Fiji. Thresh-
olding: Choosing a cuttoff value, so that every pixel below or above the threshold will be considered as
background or object, respectively.
1. Open a binary image in Fiji (Figure 2D).
2. Threshold images: Image→Adjust→Threshold; Setting: Upper slider 1, Lowe slider 2, Rest:
Default;B&W
3. Nowwe can create ROIs with ”Analyze Particles” (Figure 2E). Analyze→Analyze Particles;
Settings: Clear results, Add to Manager, Exclude on Edges. With the ”Size” and ”Circular-
ity” argument we can excluded objects which are no cells.
4. The generated ROIs can now be saved by selecting More→Save in the ROI Manager. ROIs
will be saved in a .zip-container.
Script for batch process: part1_creating threshold images
Remarks for skript usage: It can be desirable to change size and circularity of objects for batch pro-
cessing. In this case, the size=0-Infinity and circularity=0.00-1.00 arguments can be changed in the
following command-line: run(”Analyze Particles…”, ”size=0-Infinity circularity=0.00-1.00 exclude
clear add”).
3.2 Correcting for Segmentation Biases and x,y-Position of ROIs
In this step we can correct for segmentation biases we might have introduced at the segmentation
step (see step 2.2/4). Moreover, we can also correct for drift in the x, y position of the ROIs, which can
occur during filter cube change. Once we have defined the correction values they can automatically
be applied to all images using the following two scripts. Script:
• part2_manually_shift roi
• part3_manually_size_adjust
Remarks for script usage: The script applies the same corrections to all images. Please verifywhether
corrections generate reliable ROIs.
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Creating Corrected ROIs (only for batch processing)
We wrote a script that allows automated adjusting of all ROIs:
part4_creating adjusted ROIs
3.3 Extracting Cell Parameters and RFU
Here we can extract information from the ROIs we have created above. First we have to set the
parameters we want to measure (e.g. fluorescence intensity, cell size, cell shape). A full list of
parameters that Fiji can measure (incl. description) can be found here: https://imagej.nih.
gov/ij/docs/menus/analyze.html.
1. Choose the parameters you want to measure Analyze→Set Measurements; Make sure that
the option for ”Display Label” is checked.
2. Open an image and the corresponding ROI. In the ROI-Manager check the option: ”Show All”.
3. Measure parameters with: Analyze→Measure.
4. Copy the results into an Excel-file and save as .csv (separated by comma, semicolon or tab).
We wrote a script that allows automated batch processing of all images: part5_measuring
Remark for skript usage:
Image names and names of the ROIs have to correspond exactly, for the automated script to work.
We have included an option in the script that allows to change the file name (of the file loaded), if
names of images and ROIs do not correspond (e.g. CH1 and CH2; see section 4 for details).
3.4 Assigning Factor Levels to Data
From the generated file, we have extract information that are encoded in the factor name (see table
1 and table 2). We can do this in R-based ShinyApps (this step is simple to execute and will be briefly
explained in 4).
Name Area RFU
24122016_TreatmentA_Factor1_…_CH1.tif 1 1000
Table 1: The exported Excel-file from Fiji lists important image information (e.g. time, treatment,
factor level, channel) in a concatenated form under the label ”Name”.
Date Treatment Factor … Chanel Area RFU
24122016 TreatmentA Factor1 … CH1 1 1000
Table 2: The ShinyApp allows to split up the relevant information into different columns for subse-
quent analysis.
6
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4 Walkthrough with Example Dataset
This walkthrough explains the application of the Fiji scripts using representative example images.
It starts with the binary images received from ilastik.
Comments before we can start the procedure:
• Name of example image received from ilastik:
3h_control_Image002_CH1_Object Predictions.png
• ”_Object Predictions.png” is added to the original filename by ilastik and is essential for the
script to work. It is possible to remove/change this extra label by changing change the ”Ob-
ject Predictions.png”-argument in script: part1_creating threshold images; filename=re-
place(title,”Object Predictions.png”,””);;
Starting the Procedure
1. Start Fiji and open script part1_creating_threshold_images and run it. Follow the instructions.
2. Go into the folder example data\gfp) and load one of the gfp-images.
3. Load the corresponding ROI.zip-file.
4. Select the gfp image, and in the ROI-Manager check the option ”Show all”.
5. Zoom in and check alignment (size, and x/y position). To correct alignment, run script part2_man-
ually_shift roi and/or part3_manually_size_adjust. To undo the changes, ”re-load” the
ROIs or rerun the script with inverted signs (e.g − → +) using the same values. Please
remember the implemented correction values, as they will be needed in the next step. Cor-
rection factors are sensitive to scale, it might be necessary to set the scale in your image. (http:
//imagej.net/SpatialCalibration).
6. To create corrected ROIs, open and run script part4_creating_adjusted_ROIs and enter the
correction values from the previous step.
7. To measure cell features (e.g. size, RFU,…), follow the instructions from step 3.3/1 first (”Set
measurement”).
8. To extract object parameters of interest, open and run script part5_measuring. Please note,
that ilastik did the segmentation based on phase contrast images, which corresponds to channel
name ”CH1”. GFG-images were, however, recorded in channel ”CH2”. If we want to measure RFU
in GFP-images we thus have to change the name of the file, since the script requires the names
to correspond exactly. We have implemented an automated renaming option in the script. When
running the script, it first asks for the name of the channel used for segmentation (here ”CH1”)
and then the name of the channel to be analyzed (here ”CH2”). This option will simply adjust the
file names while being processed by Fiji, and it will not change the actual filename in the folder.
9. Copy results from the output table into an excel file and save as .csv (with column names) in
the folder.
(a) Download R or use a portable version.
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(b) Start R and run our script split_data_GUI.R. In a first step, the script First it will auto-
matically download and install all the necessary packages1
(c) A new tab/window in your browser will open with the graphical ShinyApp interface.
(d) Follow the instructions on the left-hand side of the interface, from top to bottom. In a
first step, upload the csv-file, then you can assign, split and rename factors. Finally, the
modified table can be exported as csv-file and used for in-depth statistical analysis and
plotting.
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CHAPTER 6
Nothing in Biology Makes Sense Except in the Light of
Evolution
Theodosius Dobzhansky 1973
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Cooperation is a ubiquitous feature in the bacterial world and especially viru-
lence is often facilitated by cooperative interactions, as in P. aeruginosa, where
cooperation is crucial to successfully colonize a hosts. Often this is facilitated
by secreted, publicly shared virulence factors [23, 94, 95, 99, 100].
In chapter 3, we used an approach that targets the secreted and publicly shared
virulence factor pyoverdine to reduced pathogenic growth and consequently
virulence in an insect model. We achieved this by exposing P. aeruginosa to
gallium (at concentrations that are not harmful to the host), which binds pref-
erentially to its siderophore, pyoverdine, rendering it useless. Moreover, we
subjected P. aeruginosa to gallium or different antibiotics (and a combination of
those) over a period of two weeks. While bacteria rapidly gained resistance to
antibiotics, gallium retained its efficacy, indicating that bacteria indeed have a
hard time to become resistant against gallium. These results support our hy-
pothesis that the anti-virulence agent gallium can be an evolution proof treat-
ment (that is a treatment to which bacteria cannot easily develop resistance).
In chapter 3, we showed that gallium-induced pyoverdine quenching (in-vitro)
is accompanied by an upregulation of pyoverdine production as a compen-
satory mechanism. This might have dramatic consequences for the regulatory
network of the pathogen and can lead to overproduction of other, regulatorily
linked, virulence factors, which would be detrimental for gallium as a treat-
ment. Therefore, in chapter 4, we investigated the effect of the manipulation of
virulence factor availability (by gallium) on virulence, the regulatory network
and the host response. We found that virulence factor availability was over-
all predictive for virulence and that manipulating virulence factor availability
feeds back the regulatory network of the pathogen. Furthermore, the immune
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response of the host was elevated, when confronted with the pathogen and with
increasing virulence factor availability. However, we did not observe increased
virulence, when gallium was present. Nevertheless, these insights show that
we need a close understanding of how any given anti-virulence agent works in
order to design effective and evolutionary robust anti-virulence treatments.
Our argument of evolutionary robustness is based on the assumption that we
targeted a shareable virulence factor. Many studies have shown the shareability
of pyoverdine in liquid cultures with millions of cells and that pyoverdine is a
virulence factor [22, 23, 37, 94–100]. However, we have little knowledge about
the shareability of pyoverdine in a less artificial setup, where diffusion of py-
overdine might be limited, due to increased viscosity (e.g. tissue or biofilms).
Therefore, we conducted experiments with surface attached bacteria and estab-
lished the physical limits of pyoverdine sharing (chapter 5). We found that py-
overdine is collectively shared, even when its diffusion is severely limited and
cell numbers are low, conditions P. aeruginosa could for example experience dur-
ing colonization of a host or within biofilms. Hence, at this stage P. aeruginosa
would be most vulnerable to therapies, which aim to inhibit its siderophore.
In the following sections, I will discuss the key insight of each chapter in a
wider context.
6.2 Gallium Therapy and Resistance Evolution
In chapter 3 we proposed gallium as a potentially evolution proof anti-virulence
treatment that reduced pathogenicity of P. aeruginosa in an insect model and in
mice [163]. Gallium binds irreversibly to pyoverdine, making it unavailable as
an iron delivery system [162]. It is predicted, that gallium should not induce
resistance, since it is targeting a secreted and collectively shared virulence fac-
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tor [96, 142] and section 2.5. Thus, routes to resistance are limited and in case
resistance arises, it is selected against. And indeed, we did not find any signs of
resistance during an experimental evolution, where bacteria were subjected to
gallium over a period of two weeks, whereas, bacteria, exposed to antibiotics,
developed resistance rapidly. But what does this mean for gallium as a potential
drug? Will there be no resistance whatsoever?
6.2.1 What is Resistance?
Resistance to a treatment is often defined as the recovery of growth [123]. Since
antibiotics kill bacteria (bactericidal) or dramatically reduce proliferation (bac-
teriostatic), growth is a good indicator for resistance. However, resistance to
an anti-virulence treatment could manifest in at least three ways: (i) recovery
of growth, (ii) restoration of virulence factor production and (iii) detection of
bypassing mechanisms.
Anti-virulence agents are not primarily designed to hinder pathogenic growth.
They disarm pathogens by targeting their virulence factors and since there is a
profound disconnect between growth and virulence factor production [97, 144],
recovery of growth alone might be not enough to define resistance. A pathogen
may recover its growth in an infection (treated with an anti-virulence agent), but
since virulence factors are quenched, it could do so in a benign, non-virulent
state, where it is causing no (or less) damage to the host. For anti-virulence
treatments, we therefore have to include full restoration of virulence (by e.g.
bypassing the virulence factor) into the definition of resistance.
6.2.2 Assessing Resistance to an Anti-Virulence Treatment
Assessing resistance to a drug can be carried out within the host (in-vivo) or
in a laboratory medium (in-vitro). Both approaches have their advantages and
disadvantages. The identification of virulence factors often involves a screen in
laboratory medium for non-essential genes that are predictive for a model-host
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system. Experiments in laboratory media are easy to perform, but simultane-
ously are very artificial, as the virulence factor might not even been deployed
(e.g. some virulence factors might require cues from a host for their expres-
sion). Such a setup differs greatly to conditions where selection for resistance
happens, inside the host [201]. Thus, resistance development to anti-virulence
drugs should be assessed in-vivo, where the inhibited virulence factors (among
other) are detrimental for the pathogen. But evolution experiments within a
host are difficult to carry out and are naturally subjected to increased variation
(introduced by the differences between hosts).
In our experiments (chapter 3), we performed the test for resistance in CAA
(casamino acids; our standard laboratory medium for iron limited experiments),
but this experiments not necessarily reflect what is happening in the host. There-
fore, we aim to investigate the potential of P. aeruginosa to develop resistance
to gallium in an ex-vivo growth medium, namely human serum 1 (HS). Hu-
man serum is a complex, protein rich medium with iron binding factors (e.g.
transferrin) [202]. It was shown that, in addition to proteases, P. aeruginosa also
requires pyoverdine to grow [202]. Moreover, we observed that QS deficient
strains (∆lasR) are unable to grow in HS, whereas a RhlR-deficient strain can
proliferate, indicating that LasR-controlled proteases are essential in HS (Rez-
zoagli C., Wilson D., Wyder S., Weigert M. and Kümmerli R., 2017, in prepa-
ration). When predigested with proteinase K, growth of P. aeruginosa was el-
evated, irrespective of pyoverdine and protease production [202]. This indi-
cates that HS promotes the production of proteases and possibly other viru-
lence factors to facilitate growth. Thus, HS combines advantages of in-vivo and
1Human Serum: Blood is collected and separated into cells and plasma. The plasma is sepa-
rated from the cells, and calcium is added to activate the clotting cascade of the plasma. Sub-
sequently the mixture is centrifuged, and the liquid product remaining is the serum. From
production sheet by Sigma Aldrich.
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in-vitro approaches to asses possible resistance mechanisms. HS could allow
more routes to resistance (e.g. virulence factors, which are not advantageous
in laboratory media, become beneficial in HS and can be used to bypass the
quenched virulence factor) than standard laboratory media and thus is a better
environment to test for resistance.
6.3 Consequences of Manipulation of Virulence
Factor Availability
In chapter 3 we established that the addition of gallium upregulates pyoverdine
production as compensatory mechanism. This might lead to increased expres-
sion of Protease IV and ETA via the genetic link described previously (section
2.3.3). Therefore, instead of reducing virulence, gallium would increase it. En-
hanced pyoverdine secretion could also affect the host as it might act as a cue
for the host to upregulate a specific immune response. An elevated immune re-
sponse could easily lead to an arms race between the host and the pathogen and
thus can cause unpredictable treatment outcomes. Therefore, we performed a
detailed analysis of the effects of anti-virulence treatments on the pathogen, its
regulatory network and the host (chapter 4).
We found that virulence factor availability did not correlate monotonously with
either pathogenic growth in-vivo, nor with virulence. We did not observe a
strong response of ETA- or Protease IV-expression to gallium in our experi-
ments. However, it is unclear if addition of gallium did not induce expression
changes of these virulence factors, or if their expression is limited due to the use
of laboratory media (non-pathogenic environment). Assessing such regulatory
changes in-vivo would be more informative, but it is difficult to recover suffi-
cient amounts of bacterial RNA from the host for later analysis. Potentially, we
could perform this experiment in HS, but it would still be contaminated with
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human RNA (from the donor). However, reduced virulence in gallium treated
larvae indicate that, if such upregulation is happening, its effect is negligible
[96, 97].
Moreover, we found that the host is reacting to the manipulation of the vir-
ulence factor pyoverdine. This implies that virulence factor availability is in-
volved in triggering host response. In humans this could be facilitated by side-
rocalin, a protein which is part of the innate immune response and able to bind
siderophores to prevent bacterial iron uptake [203]. This could slow down pa-
thogenic growth, which would give the immune system an edge and more time
to fight back the infection.
Together, these results show that we are in the need of a close understanding of
anti-virulence treatments and their effect on the bacteria and the host in order
to design effective and evolutionary robust treatments.
6.4 Perspectives
What are the perspectives of anti-virulence treatments and their potential appli-
cations in infections? In chapter 3 and 4 we proposed gallium as an resistance-
proof agent to fight P. aeruginosa infections. Our studies support the concept
of evolution proof anti-virulence treatments. But can, for example, gallium be
used as a drug to control infections?
6.4.1 Gallium as a Drug?
Gallium is not a new therapeutic agent. In its commercial, FDA-approved form
Ganite (Genta), it is used as a anti-cancer drug, relying on elevated uptake rates
of cancer cells, inhibiting iron-dependent metabolic functions [204].
In March 2016 the university of Washington started a phase 2 clinical study with
gallium in cystic fibrosis patients (ClinicalTrials.gov Identifier: NCT02354859),
which is expected to finish in April 2017. The primary goal of this study is to
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improve pulmonary function (by 5% or more) and as a secondary outcome, to
reduce abundance of P. aeruginosa in CF-lungs of participants. However, the
outcome of the study might not answer the question whether gallium helps to
reduce the virulence of P. aeruginosa in the way we proposed here, as an anti-
virulence drug. Patients eligible for the trial must have a chronic CF-associated
infection. But it is known that P. aeruginosa often loses its ability to produce py-
overdine in chronic CF-infections [98, 101, 102]. As described in chapter 3, gal-
lium can only work as an anti-virulence agent at intermediate concentrations,
where it inhibits pyoverdine, but diffusion driven gallium-uptake across the
cell membrane is presumably not taking place [96]. However if no siderophores
are present, gallium can only work by its antibacterial effect (at high concen-
trations), when it increasingly diffuses across the cell membrane, and displays
off-target effects, e.g. disrupting iron dependent processes within the cell. Con-
sequently, it becomes vulnerable to resistance mechanism, similar to the ones
known from antibiotics (e.g. efflux pumps). This shows that we have to eval-
uate the correct dose at which an anti-virulence drug has to be administered,
since too little of the drug may have no effect, but too much of it could change
it from an anti-virulence agent to a treatment with off-target effects.
Following this line of argumentation, treating chronic CF-infections with gal-
lium might not be an anti-virulence treatment. Its administration is happen-
ing too late and gallium cannot effectively work as an anti-virulence treatment
(since bacteria might no longer produce pyoverdine). This, however, raises the
question, when administration of gallium would be most effective?
6.4.2 When Would Administration of Gallium be Most
Effective?
Based on the insights we gained from our experiments in chapter 5, we know
that pyoverdine cooperation is already taking place when cell numbers are very
low and when the viscosity of the environment was elevated. We established
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that pyoverdine diffusion and sharing is happening shortly after incubation, fa-
cilitating the growth of pyoverdine non-producing strains, without the need of
cell-to-cell contact as previously claimed by Julou et al. [205]. Pyoverdine non-
producer even benefited from pyoverdine producing strains when distance be-
tween the communities was greater than 60 µm. P. aeruginosa could experience
such conditions in early stages of infection in biofilms or within soft tissue.
By administering gallium, P. aeruginosa would suddenly be deprived of a viru-
lence factor that is essential for colonization. The pathogenic community would
consist of phenotypic pyoverdine non-producers that display reduced pathogeni-
city and might not be able to efficiently colonize the host [96, 97, 163]. Moreover,
our results would imply that any individual that resumes cooperation (e.g. by
becoming resistant to gallium) will be immediately exploited by the surround-
ing phenotypic non-producers, irrespective of the viscosity of the environment.
Moreover, similar to our single cell experiments, resistant pyoverdine-producer
would upregulate investment into pyoverdine production (as a compensatory
mechanism for exploitation) at the cost of proliferation and eventually will get
out-competed by the (phenotypic) non-producer.
The results imply that P. aeruginosa would be most vulnerable to gallium-me-
diated pyoverdine quenching when cell numbers are very low, or even as a
preemptive treatment.
6.4.3 The Future of Anti-Virulence Treatments
Anti-virulence treatments can help to manage infections of multi-resistant pa-
thogens, as they have many advantages: (i) they can reduce virulence of patho-
gens, (ii) can be designed to be resistant-proof and (iii) by their innate complex-
ity, they can be very specific to a pathogen. Though, being a step forward in the
right direction, anti-virulence treatments also come with drawbacks. Finding
such drugs and evaluating all aspects of their mode of action and impact on
the host and the pathogen (as discussed in this thesis) is difficult. Furthermore,
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anti-virulence treatments may not reach the efficiency of antibiotics. But this is
not necessarily what they are supposed to do, as they can be part of a combi-
nation therapy. Anti-virulence treatments can, for example, help to break up
biofilms, making the pathogen more accessible for clearance with conventional
antibiotics [161]. It has been shown that multi-resistant P. aeruginosa-strains,
treated with a quorum quenching lactonase (the lactonase AiiA2), shows higher
susceptibilities to gentamicin and ciprofloxacin, compared to a lactonase-free
treatment [206].
As established earlier, anti-virulence treatments reduce the virulence of a patho-
gen and also can slow down their growth. This could give the immune system
an edge and the chance to mount an appropriate immune response to fight back.
Anti-virulence drugs are no weapons, as powerful as antibiotics were, when
they entered the market in the 1940s, but they can help to manage infections, in
cases where these "powerful" weapons fail.
2AiiA is an enzyme produced by Bacillus thuringiensis to degrade AHLs [165].
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